

# **CURRICULUM VITAE**

**BENEDITO A. CARNEIRO (FILHO), MD, MSc**

**Business or Mailing Address:** Brown Medicine  
Division of Hematology/Oncology  
The Rhode Island Hospital  
593 Eddy Street  
Providence, RI 02903

**Business Phone Number:** 401-444-4830

**Business Fax Number:** 401-444-4148

**Email:** [Benedito\\_Carneiro@Brown.edu](mailto:Benedito_Carneiro@Brown.edu)

## **EDUCATION**

**Medical School** **1994 – 2000**  
School of Medicine (6-year program), Federal University  
of Ceará, Fortaleza, CE, Brazil

**Postdoctoral degree** **2008 – 2010**  
Master of Science in Clinical Research, The Institute for  
Clinical Research Education, Clinical and Translational  
Science Institute, University of Pittsburgh, Pittsburgh, PA

## **POSTGRADUATE TRAINING**

**Residency** **2003 – 2006**  
Internal Medicine Residency McGaw Medical Center of  
Northwestern University/Evanston Hospital, Evanston, IL

**2006 – 2007**  
Chief Medical Resident, Evanston Northwestern  
Healthcare, Evanston, IL

**Fellowship**

**2001 – 2003** Action for Building Capacity Research Fellow (Fogarty  
International Center, NIAID, NIH), Division of Infectious  
Diseases and International Health, Department of  
Medicine, University of Virginia, Charlottesville, VA

**2007 – 2010**

Hematology/Oncology Fellow, Division of  
Hematology/Oncology, Department of Medicine,  
University of Pittsburgh, Pittsburgh, PA

**2014 – 2015**

Developmental Therapeutics Fellow, Northwestern  
Medicine Developmental Therapeutics Institute,  
Northwestern University Feinberg School of Medicine

### **POSTGRADUATE HONORS AND AWARDS**

**1996**

Best Oral Presentation, Basic Science Research, XXVI  
National Medical Students Scientific Meeting, Maceio, AL,  
Brazil.

**1996**

Pharmacology Teaching Assistant Scholarship, Department  
of Pharmacology, School of Medicine, Federal University  
of Ceará, Fortaleza, CE, Brazil.

**1999**

Medical Oncology Teaching Assistant Scholarship,  
Department of Pharmacology, School of Medicine, Federal  
University of Ceará, Fortaleza, CE, Brazil.

**2003**

Outstanding Research Presentation, The 22nd Annual  
Department of Medicine Research Day, University of  
Virginia, Charlottesville, VA.

**2004**

Intern of the Year Award, McGaw Medical Center of  
Northwestern University/Evanston Hospital, Evanston, IL.

**2005**

The A. Zamin Rizavi MD Award, Resident that Best  
Exemplifies the Admirable Traits of the late Dr Rizavi,  
McGaw Medical Center of Northwestern  
University/Evanston Hospital, Evanston, IL.

**2006**

Resident of the Year Award, McGaw Medical Center of  
Northwestern University/Evanston Hospital, Evanston, IL.

**2016**

Feinberg School of Medicine Excellence in Teaching  
Award, Division of Hematology/Oncology, Department of  
Medicine, Northwestern University

### **PROFESSIONAL LICENSES AND BOARD CERTIFICATION**

- American Board of Internal Medicine (2007)
- American Board of Internal Medicine Medical Oncology (2013)
- State of Illinois Medical License 036-115617
- State of Rhode Island Medical License MD15932
- United States DEA number FC4493398

## **ACADEMIC APPOINTMENTS**

<b>2006 – 2007</b>	Clinical Instructor, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
<b>2012 – 2013</b>	Assistant Professor of Medicine, School of Medicine, University of Fortaleza, Fortaleza, CE, Brazil
<b>2014 – 2015</b>	Instructor in Medicine-Hematology/Oncology, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine
<b>2015 – 2017</b>	Assistant Professor in Medicine - Hematology/Oncology, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine
<b>2016 – 2017</b>	Co-Director, Developmental Therapeutics Program, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine
<b>2016 – 2017</b>	Director, Developmental Therapeutics Fellowship, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine
<b>2017 – 2022</b>	Assistant Professor of Medicine, Division of Hematology/Oncology, The Warren Alpert Medical School, Brown University, Providence, RI
<b>2017 – present</b>	Director of Clinical Cancer Research, Director of Cancer Drug Development Program (Phase I), Brown University Health Cancer Institute
<b>2017 – present</b>	Associate Director, Division of Hematology/Oncology, Department of Medicine, The Warren Alpert Medical School, Brown University
<b>2019 – present</b>	Co-Leader Cancer Therapeutics Program, Legorreta Cancer Center at Brown University
<b>2019 – present</b>	Chair, Scientific Review and Monitoring Committee (SRMC), Legorreta Cancer Center at Brown University
<b>2022 – present</b>	Associate Professor of Medicine (Research Track), Department of Medicine, Division of Hematology/Oncology, The Warren Alpert Medical School, Brown University, Providence, RI
<b>2024 – present</b>	Clinical Director of RNA-based Cancer Therapeutics, Brown RNA Center, Brown University

## **HOSPITAL APPOINTMENTS**

<b>2000 – 2001</b>	Internal Medicine Physician, Paraipaba Hospital, Paraipaba, CE, Brazil
<b>2010 – 2014</b>	Medical Oncologist, General Hospital of Fortaleza, Fortaleza, CE, Brazil
<b>2016 – 2017</b>	Medical Director, Developmental Therapeutics Program Clinic, Olson Pavilion, Northwestern Memorial Hospital
<b>2017 – present</b>	Associate Director, Division of Hematology/Oncology, Department of Medicine, Alpert Medical School, Brown University

## **HOSPITAL COMMITTEES**

<b>2014 – 2017</b>	Steering Committee, Bristol-Myers Squibb Rare Malignancies Program and Developmental Therapeutics Program Alliance, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine
<b>2016 – 2017</b>	Cancer Quality Committee, Northwestern Memorial Hospital
<b>2017 – present</b>	Brown University Health Cancer Institute Operations and Performance Monitoring Committee
<b>2018 – present</b>	Brown University Health Research Advisory Committee

## **UNIVERSITY COMMITTEES**

<b>2014 – 2015</b>	Scientific Review Committee, The Robert H Lurie Comprehensive Cancer Center, Northwestern University
<b>2014 – 2017</b>	Institutional Review Board, Northwestern University
<b>2014 – 2017</b>	Clinical Trial Audit Committee, The Robert H Lurie Comprehensive Cancer Center, Northwestern University
<b>2017 – present</b>	Brown University Oncology Research Group (BrUOG), Executive Committee Member
<b>2018</b>	Faculty Search Committee for Scientist or Physician-scientist Cancer Biology, Department of Pathology and Laboratory Medicine, Joint Program in Cancer Biology, Alpert Medical School of Brown University
<b>2022</b>	Faculty search committee for Phase I oncologist in the Department of Medicine, Alpert Medical School of Brown University
<b>2022</b>	Faculty search committee for Immuno-oncologist in the Department of Medicine, Alpert Medical School of Brown University

<b>2022</b>	Faculty search committee for Director of Anatomic Pathology, Department of Pathology and Laboratory Medicine, Alpert Medical School of Brown University
<b>2019 – present</b>	Co-Chair Genitourinary Committee, Brown University Oncology Research Group (BrUOG)
<b>2021 – present</b>	Co-Chair Phase I Committee, Brown University Oncology Research Group (BrUOG)
<b>2025</b>	Faculty search committee for Associate to Full Professor, Legorreta Cancer Center, Department of Pathology and Laboratory Medicine, Alpert Medical School of Brown University

### **NATIONAL COMMITTEES**

<b>2015 – 2017</b>	Southwest Oncology Group (SWOG) Genitourinary Committee
<b>2016 – 2017</b>	National Comprehensive Cancer Network (NCCN), Testicular Cancer Guideline Panel
<b>2020 – present</b>	Alliance GU Committee
<b>2020</b>	Program Committee for the American Association for Cancer Research (AACR) Annual Meeting, Biological Therapeutic Agents Section of the Experimental and Molecular Therapeutics Subcommittee
<b>2020 – 2023</b>	American Society of Clinical Oncology (ASCO), Annual Meeting Scientific Program Committee, Developmental Therapeutics – Immunotherapy
<b>2020 – 2024</b>	American Association for Cancer Research (AACR) Annual Meeting, Clinical Trials Committee
<b>2024 – present</b>	Early-Phase Trials Moderator, WIN (Worldwide Innovative Networking) Consortium in Personalized Cancer Medicine, Molecular Tumor Board

### **MEMBERSHIP IN SOCIETIES**

<b>2007 – present</b>	American Association for Cancer Research
<b>2007 – present</b>	American Society of Clinical Oncology
<b>2018 – present</b>	European Society for Medical Oncology

### **JOURNAL REVIEWER AND EDITORIAL BOARD**

#### **Editorial boards**

<b>2018 – 2022</b>	American Journal of Clinical Oncology, Associate Editor
<b>2019 – present</b>	Cancer Biology & Therapy, Editorial Board
<b>2024 – present</b>	Oncotarget, Editorial Board

## Reviewer

Cancer Discovery, Clinical Cancer Research, Cancer Letters, Nature Communications, Frontiers in Oncology, Cancer Research Communications, Oncology and Hematology Review, Journal of Interferon & Cytokine Research, PLOS One, British Journal of Cancer, Thyroid, eLife

## GRANT REVIEWER

**2015** Austrian Science Fund

**2021-present** Robert E. Lee and Clara Guthrie Patterson Trust Mentored Research Award:  
Clinical, Health Services and Policy Research Program

## PUBLICATIONS LIST

**h-index 43** (Google Scholar 12/2024)

### **I. Original, peer-reviewed publications.**

1. Souza FGM, Landim RM, Perdigão FB, Morais RM, **Carneiro-Filho BA**. Consumo de drogas e desempenho acadêmico entre estudantes de medicina no Ceará (Drug use and academic achievement among medical students from Ceará). *Revista de Psiquiatria Clínica* 1999; 26(4):188-194
2. **Carneiro-Filho BA**, Souza ML, Lima AA, Ribeiro RA. The effect of tumor necrosis factor (TNF) inhibitors in *clostridium difficile* toxins-induced paw oedema and neutrophil migration. *Pharmacology and Toxicology* 2001; 88(6):313-8. PMID 11453371
3. Viana CF, Melo DH, **Carneiro-Filho BA**, Michelin MA, Brito GA, Cunha FQ, Lima AA, Ribeiro RA. Pro-inflammatory effects of cholera toxin: Role of tumor necrosis factor. *Toxicon* 2002; 40(10):1487-94. PMID 12368119
4. Brito GA, Fujii J, **Carneiro-Filho BA**, Lima AA, Obrig T, Guerrant RL. Mechanism of *clostridium difficile* toxin A induced apoptosis in T84 cells. *Journal of Infectious Diseases* 2002;186(10):1438-47. PMID 12404159
5. **Carneiro-Filho BA**, Lima IP, Araujo DH, Cavalcante MC, Carvalho GH, Brito GA, Lima V, Monteiro SM, Santos FN, Ribeiro RA, Lima AA. Intestinal barrier function and secretion in Methotrexate induced rat intestinal mucositis. *Digestive Diseases and Sciences* 2004; 49(1):65-72. PMID 14992437
6. **Carneiro-Filho BA**, Oria RB, Wood Rea K, Brito GA, Fujii J, Obrig T, Lima AA, Guerrant RL. Alanyl-glutamine hastens morphological recovery from 5-Fluorouracil induced mucositis in mice. *Nutrition* 2004; 20:934-41. PMID 15474885
7. Brito GA, **Carneiro-Filho B**, Oria RB, Destura RV, Lima AA, Guerrant RL. Clostridium difficile toxin A induces intestinal epithelial cell apoptosis and damage: Role of Gln and Ala-Gln in toxin A effects. *Digestive Diseases and Sciences* 2005; 50(7):1271-78. PMID 16047471
8. Alcantara CS, Jim XH, Brito GA, **Carneiro-Filho BA**, Barrett LJ, Carey RM, Guerrant RL. Angiotensin II subtype 1 receptor blockade inhibits clostridium difficile toxin A-induced intestinal secretion in a rabbit model. *Journal of Infectious Diseases* 2005; 191(12):2090-6. PMID 15897995
9. **Carneiro BA**, Fujii J, Brito GA, Alcantara C, Oria RB, Lima AA, Obrig T, Guerrant RL. Caspase and bid involvement in *clostridium difficile* toxin A-induced apoptosis and

- modulation of toxin A effects by glutamine and alanyl-glutamine *in vivo* and *in vitro*. *Infection and Immunity* 2006; 74(1):81-7. PMID 16368960
10. **Carneiro BA**, Watkin WG, Mehta UK, Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. *Cancer Investigation* 2006; 24(4):396-400. PMID 16777692
  11. **Carneiro BA**, Kaminer L, Eldibany M, Sreekantaiah C, Kaul K, Locker GY. Oxaliplatin-related acute myelogenous leukemia. *Oncologist* 2006; 11(3):261-2 PMID 16549810
  12. **Carneiro BA**, Brand RE, Fine E, Knop RH, Khandekar JD, Uhlig W, Locker GY. Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with advanced pancreatic carcinoma. *Cancer Investigation* 2007; 25(5):366-71 PMID 17661212
  13. Fujii J, Wood K, Matsuda F, **Carneiro-Filho BA**, Schlegel KH, Yutsudo T, Binnington-Boyd B, Lingwood CA, Obata F, Kim KS, Yoshida SI, Obrig T. Stx2 causes apoptosis in human brain microvascular endothelial cells via CHOP. *Infection and Immunity* 2008; 76(8):3679-89. PMID 18541659
  14. **Carneiro BA**, Ramanathan RK, Smitha KS, Lembersky BC, Stoller RG, Lancaster SL, Pinkerton RA, Crandall TL, Schmotzer AR, Potter DM, Bahary N. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. *Clinical Colorectal Cancer* 2012; 11(1):53-9. PMID 21813336
  15. **Carneiro BA**, Elvin JA, Kamath SD, Ali SM, Paintal AS, Restrepo A, Berry E, Giles FJ, Johnson ML. FGFR3-TACC3: a novel gene fusion in cervical cancer. *Gynecol Oncol Rep* 2015; 13:53-6. PMID 26425723
  16. Chae YK, Anker J, **Carneiro B**, Chandra S, Kaplan J, Kalyan A, Santa-Maria C, Platanias L, Giles F. Genomic landscape of DNA repair genes in cancer. *Oncotarget* 2016; 7(17): 23312-21 PMID 27004405.
  17. Chae YK, Gagliato Dde M, Pai SG, **Carneiro B**, Mohindra N, Giles FJ, Ramakrishnan-Geethakumari P, Sohn J, Liu S, Chen H, Ueno N, Hortobagyi G, Gonzalez-Angulo AM. The association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer. *PLoS One* 2016; 11(4): 0152585. PMID 27055285
  18. Chae YK, Davis AA, **Carneiro BA**, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. *Oncotarget* 2016; 7(40):65364-65373 PMID 27588476
  19. Meeks J, **Carneiro B\***, Pai SG, Oberlin D, Rademaker A, Fedorchak, Balasubramanian S, Elvin J, Beaubier N, Giles F. Genomic characterization of high-risk non-muscle invasive bladder cancer. *Oncotarget* 2016; 7(46): 75176-75184 PMID 27750214 (\*) co-first author
  20. Costa R, **Carneiro B**, Agulnik M, Rademaker A, Pai S, Cristofanilli M, Villaflor V. Sosman J, Giles F. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. *Oncotarget* 2017; 8(5):8910-8920. PMID 27852042
  21. Costa R, Gill N, Rademaker AW, **Carneiro BA**, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ. Systematic analysis of early phase clinical studies for patients with breast cancer: inclusion of patients with brain metastasis. *Cancer Treat Rev* 2017; 55:10-15 PMID 28279895
  22. Costa R, Costa RB, Talamantes SM, Helenowski I, Peterson J, Kaplan J, **Carneiro BA**, Giles FJ, Gradishar WJ. Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: palbociclib and ribociclib. *Breast* 2017; 35:1-7 PMID 28618307

23. Costa R, Costa RB, Talamantes SM, Helenoswki I, **Carneiro BA**, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. *Oncotarget* 2017 PMID 28733528
24. Stoller R, Schmitz JC, Ding F, Puhalla S, Belani C, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Czambel RK, **Carneiro BA**, Kontopodis E, Hershberger P, Rashid M, Giranda V, Chen A, Chu E, Beumer JH. Phase I study of veliparib in combination with gemcitabine. *Cancer Chemotherapy and Pharmacology* 2017 80(3):631-43 PMID 28770300
25. Pai S, **Carneiro BA**, Kalyan A, Costa R, Chae Y, Mahalingam D, Giles FJ. Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer. *Journal of Gastrointestinal Oncology* 2017; 8(5):858-66 PMID 29184690
26. Costa RB, Costa R, Kaplan J, Cruz MR, Shah H, Matsangou M, **Carneiro B**. A rare case of glioblastoma multiforme with osseous metastases. *Case Reports Oncol Med* 2017;2938319 PMID 29201475
27. **Carneiro BA**, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Kuzel TM, Fan A, Chae YK, Hussain M, Cristofanilli M, Abdulkadir SA, Giles FJ. Acquired resistance to the PARP inhibitor olaparib in BRCA2-associated prostate cancer due to biallelic BRCA2 reversion mutations restoring both germline and somatic loss of function mutations. *JCO Precision Oncology* 2018; 2: 1-5 PMID 31501807
28. Zhang Q, Helfand BT, **Carneiro BA**, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM. Efficacy against human prostate cancer by prostate-specific membrane antigen-specific, transforming growth factor- $\beta$  insensitive genetically targeted CD8<sup>+</sup> T-cells derived from patients with metastatic castrate-resistant disease. *European Urology* 2018; 73(5):648-652 PMID 29275833.
29. Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhawe MA, Rademaker A, Miller C, **Carneiro BA**, Mahalingam D, Chae YK. Systematic review and meta-analysis of selected toxicities of approved *ALK* inhibitors in metastatic non-small cell lung cancer. *Oncotarget* 2018; 9(31):22137-146 PMID 29774128
30. **Carneiro BA**, Pamarthy S, Shah AN, Sagar V, Unno K, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross J, Gay L, Elvin J, Ali S, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA. Anaplastic lymphoma kinase mutation (*ALK* F1174C) in a small cell carcinoma of the prostate and molecular response to alectinib. *Clin Cancer Res* 2018;24(12):2732-39 PMID 29559559.  
*This study identified a new therapeutic target in small cell carcinoma of the prostate, a rare and aggressive subtype of prostate cancer.*
31. Chae YK, Chiec L, Adney SK, Waitzman J, Costa R, **Carneiro B**, Matsangou M, Agulnik M, Kopp P, Giles F. Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. *Oncotarget* 2018;9(46):28281-89. PMID 29963277
32. Marks EI, Pamarthy S, Dizon D, Birnbaum A, Yakirevich E, Safran H, **Carneiro BA**. *ROS1-GOPC/FIG*: a novel gene fusion in hepatic angiosarcoma. *Oncotarget* 2019;10(2):245-51 PMID: 30719217
33. Alves da Silva AV, Martins-Neto F, de Oliveira ACSM, **Carneiro BA**, Alves M, Nogueira CD, Tavora F. The frequency of high PD-L1 expression is low in lung adenocarcinoma patients from northeast Brazil. *Surgical and Experimental Pathology* 2019 2,4 <https://doi.org/10.1186/s42047-019-0031-1>



34. Chanzá NM, Xie W, Bilen MA, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, **Carneiro BA**, Heng DY, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear cell renal carcinoma: a multicenter retrospective cohort analysis. *Lancet Oncol* 2019; 20(4):581-590 PMID 30827746
35. Oliveira ACDSM, Silva AVAD, Alves M, Cronemberger E, **Carneiro BA**, Melo JC, Martins Neto F, Tavora F. Molecular profile of non-small cell lung cancer in northeastern Brazil. *J Bras Pneumol* 2019; 45(3):e20180181 PMID 31166373
36. Yakirevich E, Madison R, Fridman E, Mangray S, **Carneiro BA**, Lu S, Cooke M, Bratslavsky G, Webster J, Ross JS, Ali SM. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. *Eur Urology Oncol* 2019 PMID 31412008
37. Tatsi C, Faucz FR, Blavakis E, **Carneiro BA**, Lyssikatos C, Belyavskaya E, Quezado M, Stratakis CA. Somatic PRKAR1A gene mutation as a cause of non-syndromic metastatic large-cell calcifying Sertoli cell tumor. *Journal of the Endocrine Society* 2019; 3(7):1375-1382 PMID 31286102
38. Rini BI, Plimack ER, Stus V, Gafanov R, et al. \* Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2019; 380(12):1116-27 (\*member of the investigative team cited in the appendix of the manuscript).
39. **Carneiro BA**, Konda B, Costa RB, Costa, RLB, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ. Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial. *J Clin Endocrinol Metab* 2019; 104(12):6193-6200 PMID 31276163.
40. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel S, **Carneiro BA**, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion *BRCA* mutations among patients with advanced solid tumors. *Clinical Cancer Research* 2020;26(11):2546-2555 PMID 32034076
41. Vatapalli R, Sagar V, Rodriguez Y, Zhao J, Unno K, Pamarthy S, Lysy B, Anker J, Han H, Yoo Y, Truica M, Chalmers Z, Giles F, Yu J, Chakravarti D, **Carneiro B**, Abdulkadir S. Histone Methyltransferase DOT1L Coordinates AR and MYC Stability in Prostate Cancer. *Nature Communications* 2020; 11(1):4153 PMID 32814769
42. Henrich SE, McMahon KM, Plebanek MP, Calvert AE, Feliciano T, Parrish S, Tavora F, Mega A, De Souza A, **Carneiro BA\***, Thaxton CS. Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner. *J Extracell Vesicles* 2020;10(2):e12042 PMID 33408816 (\*) co-corresponding author
43. Yakirevich E, Pavlick DC, Perrino C, Stanton M, Lu S, **Carneiro B**, Bratslavsky G, Ross JS. NF2 Tumor Suppressor Gene Inactivation in Advanced Papillary Renal Cell Carcinoma. *Am J Surg Pathol* 2021; 45(5):716-718 PMID 32925192
44. Borden BA, Baca Y, Xiu J, Tavora F, Winer I, Weinberg BA, Vanderwalde A, Darabi S, Korn WM, Mazar A, Giles FJ, Crawford L, Safran H, El-Deiry W, **Carneiro BA**. The Landscape of Glycogen synthase kinase-3 beta (GSK-3 $\beta$ ) Genomic Alterations in Cancer. *Mol Cancer Ther* 2021; 20(1): 183-190 PMID 33087512

45. Marks EI, Matera R, Olszewski AJ, Yakirevich E, El-Deiry WS, Safran H, **Carneiro BA**. Mutations in DNA repair genes and clinical outcomes of patients with metastatic colorectal cancer receiving oxaliplatin or irinotecan-containing regimens. *Am J Clin Oncol* 2021; 44(2):68-73 PMID 33298767
46. Alves M, Borges DP, Kimberly A, Martins Neto F, Oliveira AC, De Sousa JC, Nogueira CD, **Carneiro BA**, Tavora F. Glycogen synthase kinase-3 beta expression correlates with worse overall survival in non-small cell lung cancer—a clinicopathological series. *Front Oncol* 2021;11:621050 PMID 33767989
47. Golijanin B, Gershman B, De Souza A, Kott O, **Carneiro BA**, Mega A, Golijanin D, Amin A. p53 Expression, Programmed Death-Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma. *Front Oncol* 2021; 11:651754 PMID 33968753
48. Powles T, Csoszi T, Ozguroglu M, Matsubara N, et al. (\*) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomized, open-label, phase 3 trial. *Lancet Oncol* 2021; 22(7):931-945 PMID 34051178 (\*member of the investigators team).
49. Jhaveri AV, Zhou L, Ralff MD, Lee YS, Navaraj A, **Carneiro BA**, Safran H, Prabhu VV, Allen JE, Ross EA, Lee S, El-Deiry WS. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis and significantly delays PDAC xenograft growth. *Cancer Biology and Therapy* 2021; 22(10-12):607-618 PMID 34856854
50. Kouchkovsky I, Rao A, **Carneiro BA**, Zhang Li, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris P, Ryan CJ, Szmulewitz R, Aggarwal R. A phase 1b/2 study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer. *Clin Cancer Research* 2022;28(8):1531-39 PMID 35176163
51. Odia Y, Cavalcante L, Safran H, Powell SF, Munster PN, Ma WW, **Carneiro BA**, Bastos, BR, Mikrut S, Mikrut W, Giles FJ, Sahebjam S. Malignant Glioma Subset from Actuate 1801: Phase 1/1/22 Study of 9-ING-41, GSK- 3 $\beta$  Inhibitor, Monotherapy or Combined with Chemotherapy for Refractory Malignancies. *Neuro-Oncology Advances* 2022; 4(1):vdac012 PMID 35402914
52. LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJ, Moreno V, **Carneiro BA**, Devriese LA, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, Medeiros BC, Calvo E. Eftozanermin Alfa (ABBV-621) Monotherapy in Patients With Previously Treated Solid Tumors: Findings of a Phase 1, First-in-Human Study. *Invest New Drugs* 2022; Apr 25;1-11 PMID 35467243
53. Hsu A, Huntington K, De Souza A, Zhou L, Olszewski AJ, Makwana NP, Treaba DO, Cavalcante L, Giles FJ, Safran H, El-Deiry WS, **Carneiro BA**. Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3 $\beta$ ) inhibitor, in refractory adult T-Cell leukemia/lymphoma. *Cancer Biology and Therapy* 2022; 23(1):417-423 PMID 35815408
54. Darabi S, Braxton DR, Xiu J, **Carneiro BA**, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry W, Demeure MJ. Reversion mutations in BRCA1/BRCA2 genes in Patients Treated with Poly ADP-ribose polymerase (PARP) Inhibitors or Platinum-Based Agents. *Medicina (Kaunas)* 2022; 58(12):1818 PMID 36557020.
55. **Carneiro BA**, Papadopoulos KP, Strickler J, Lassman A, Waqar S, Chae YK, Patel J, Shacham-Shmueli E, Kelly K, Khasrqw M, Bestvina CM, Merrell R, Ansell P, Li R, Jin J, Anderson M, Reilly EB, Morrison-Thiele G, Patel K, Robinson RR, Neagu Aristide MR, Gan HK. Phase I Study of Anti-EGFR Antibody-Drug Conjugate Serclutamab

- Talirine: Safety, Pharmacokinetics, and Antitumor Activity in Advanced Glioblastoma. *Neuro-Oncol Advances* 2022; 5(1):vdac183 eCollection 2023 PMID 36814898
56. De Souza A, Mega A, Douglass J, Olszewski A, Uzun ED, Uzun A, Chou C, Duan F, Wang J, Ali A, Golijanin D, Holder S, Lagos G, Safran H, El-Deiry W, **Carneiro BA**. Clinical features of patients with *MTAP*-deleted advanced bladder cancer. *Am J Cancer Res* 2023; 13(1):326-339 PMID 36777505
  57. Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, Collier KA, Rathi N, Li H, Elias R, Martinez-Chanza N, Rose TL, Harshman LC, Gopalakrishnan D, Vaishampayan U, Zakharia Y, Narayan V, **Carneiro BA**, Mega A, Meguid C, George S, Brugarolas J, Agarwal N, Mortazavi A, Pal S, McKay RR, Lam ET. Metastatic Renal Cell Carcinoma to the Pancreas and Other Sites – A Multicenter Retrospective Study. *eClinicalMedicine* 2023;60:102018. PMID 37304495
  58. Hacking SM, Pavlick D, Wang Y, **Carneiro BA**, Mullally M, Lu S, Canepa M, Bratslavsky G, Jacob J, Necchi A, Spiess PE, Wang L, Yakirevich E, Ross J. Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy. *Oncologist* 2023; 28(7):e508-e519 PMID 36917021
  59. Huntington KE, Louie AD, Srinivasan PR, Schorl C, Lu S, Silverberg D, Newhouse D, Wu Z, Zhou L, Borden BA, Giles FJ, Dooner M, **Carneiro BA**, El-Deiry WS. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. *Int J Mol Sci* 2023; 24(13):10870 PMID: 37446056
  60. Di Cristofano FR, Fong MW, Huntington KE, **Carneiro BA**, Zhou L, El-Deiry WS. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis. *Am J Cancer Res*. 2023;13(1):307-325. PMID 36777502
  61. Tahir SK, Calvo E, **Carneiro BA**, Yuda J, Shreenivas A, De Jonge M, Devriese L, Gietema J, Ishizawa K, Moreno V, Biesdorf C, Smith M, Cheng D, Motwani M, Modi D, Buchanan G, Morgan-Lappe S, Medeiros BC, Phillips DC. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. *Blood* 2023; 141(17):2114-26. PMID 36720090
  62. Cavalcante L, Deshmukh SK, Ribeiro JR, **Carneiro BA**, Dizon DS, Angara K, Mattox T, Wu S, Xiu J, Walker P, Oberley M, Nabhan C, Huang H, Antonarakis ES. Opposing roles of SPOP mutations in human prostate and endometrial cancers. *JCO Precision Oncology* 2023;e2300088 PMID 37677121
  63. Hwang J, Shi X, McGrath J, Arnoff TE, Xiu J, Walker P, Bergom HE, Day A, Ahmed S, Tape S, Makovec A, Ali A, Shaker RM, Toye E, Passow R, Lozada JR, Wang J, Lou E, Mouw E, **Carneiro BA**, Heath E, McKay RR, Korn MW, Nabhan C, Ryan CJ, Antonarakis ES. Metastatic Prostate Cancers with *BRCA2* versus *ATM* Mutations Exhibit Divergent Clinical Outcomes and Molecular Features. *Clin Cancer Res* 2023 PMID 37126020
  64. Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, Mettu NB, **Carneiro BA**, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Reis-Filho JS, Silverman IM, Rosen E. Camonsertib, a novel, potent ataxia telangiectasia and Rad3-related kinase (ATR) inhibitor in DNA damage response biomarker-selected advanced solid tumors: A clinical and translational phase 1 trial. *Nature Medicine* 2023; 29(6):1400-1411 PMID 37277454

65. **Carneiro BA**, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma WW, Coveler AL, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weisskittel T, Li H, Borden BA, Harvey RD, Sahebjam S, Cervantes A, Koukol A, Mazar AP, Steeghs N, Kurzrock R, Giles FJ, Munster P. Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. *Clin Cancer Res* 2024;30(3):522-531 PMID 37982822
66. Rodrigues AKA, Silva PG, Nogueira C, Ferreira SS, Cordeiro J, **Carneiro B**, Tavora F. Expression of tumoral GSK3- $\beta$ , PD-L1, and CD8 cell density in urothelial carcinomas, association with tumor grade and overall survival. *Am J Clin Exp Immunol* 2023 PMID 38022872
67. Wei S, Krause HB, Geynisman DM, Elliott, Kutikov A, Uzzo RG, Pei J, Barata P, **Carneiro BA**, Heath E, Ryan C, Farrell A, Nabhan C, Ali-Fehmi R, Naqash AF, Argani P, McKay RR. Molecular Characterization of *TFE3*-rearranged Renal Cell Carcinoma, A Comparative Study with Papillary and Clear Cell Renal Cell Carcinomas. *Modern Pathology* 2024; 37(2):100404 PMID 38104891
68. Rosen E, Yap T, Lee E, Højgaard M, Mettu N, Lheureux S, **Carneiro B**, Plummer R, Fretland AJ, Ulanet D, Xu Y, McDougall R, Koehler M, Fontana E. Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Camonsertib. *Clin Cancer Res* 2024; 30(4):687-694 PMID 38078898
69. Zhang S, Huntington KE, Zhou L, Seyhan AA, Kun B, **Carneiro BA**, Kreiling J, Sedivy JM, El-Deiry WS. TRAIL pathway suppression of cancer cell growth and immune cell-mediated tumor cell-killing in a senescent fibroblast-constructed tumor microenvironment. *bioRxiv* 2023.11.30.569479; doi: <https://doi.org/10.1101/2023.11.30.569479>
70. Pinho-Schwermann M, **Carneiro BA**, Carlsen L, Huntington KE, Srinivasan PR, George A, Tajiknia V, MacDonald W, Purcell C, Zhou L, DeSouza A, Safran HP, El-Deiry WS. Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade. *bioRxiv* 2023.11.15.567201;doi.org/10.1101/2023.11.15.567201
71. Hadfield MJ, Safran H, Purbhoo MA, Grossman JE, Buell JS, **Carneiro BA**. Overcoming Resistance to Programmed Cell Death Protein 1 (PD-1) Blockade with Allogeneic Invariant Natural Killer T-Cells (iNKT). *Oncogene* 2024; 43(10):758-762 PMID 38281989
72. Patel SP, Gordoa TA, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, **Carneiro BA**. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. *J Immunotherapy Cancer* 2024; 12(2):e007340 PMID 38309722
73. Fontana E, Rosen E, Lee EK, Højgaard M, Mettu NB, Lheureux S, **Carneiro BA**, Cote GM, Carter L, Plummer R, Mahalingam D, Fretland AJ, Schonhoft JD, Silverman IM, Wainszelbaum M, Xu Y, Ulanet D, Koehler M, Yap TA. ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). *J Natl Cancer Inst* 2024;116(9):1439-1449 PMID 38710487
74. Tran B, Voskoboynik M, Bendell J, Gutierrez M, Lemech C, Day D, Frentzas S, Garrido-Laguna I, DelNagro C, Wang F, Das M, **Carneiro BA**. A phase I study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. *Immunotherapy* 2024; 16:759-774 PMID 39264730
75. Davar D, **Carneiro BA**, Dy GK, Sheth S, Borad MJ, Harrington K, Patel SP, Galanis E, Samson A, Agrawal S, Chen Z, Fan C, Gong M, Burton J, Tu E, Durham N, Laubscher

- K, Arnaldez F, Zamarin D. Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. *J Immunotherapy Cancer* 2024; 12(11): e009336 PMID 39551600
76. Li J, Yang A, **Carneiro BA**, Uzun E, Massingham L, Uzun A. Variant Graph Craft (VGC): A Comprehensive Tool for Analyzing Genetic Variation and Identifying Disease-Causing Variants. *BMC Bioinformatics* 2024; 25(1):288 PMID 39227781
  77. **Carneiro BA**, Jotte R, Gabrail N, Wentzel K, Huang F, Chaturvedi S, Weispenning A, Hiemeyer F, Morcos P, Soler L, Childs BH, Hansen AR. Safety and efficacy of copanlisib in combination with nivolumab: a Phase Ib study in patients with advanced solid tumors. *Cancer Res Commun* 2025; 5(3):444-457 PMID 39927513
  78. Lozada JR, Elliott A, Evans MG, Wacker J, Storey KM, Egusa EA, Zorko NA, Kumar A, Crymes A, Heath EI, **Carneiro BA**, Soares HP, Cichocki F, Miller JS, Lou E, Beltran H, Antonarakis ES, Ryan CJ. Expression Patterns of DLL3 Across Neuroendocrine and Non-Neuroendocrine Neoplasms Reveals Broad Opportunities for Therapeutic Targeting. *Cancer Res Commun* 2025; 5(2):318-326 PMID 39874041
  79. Mahalingam D, Saeed A, Powell SF, Huerta M, Sahai V, Coveler AL, Davis EJ, Steeghs N, Mulcahy M, Raufi AG, Cavalcante L, Cervantes A, Berlin J, Weisskittel T, Ugolkov A, Mazar AP, Mikrut W, Smith S, Giles FJ, **Carneiro BA**. Phase 2 Study of Elraglusib (9-ING-41), a GSK-3 $\beta$  Inhibitor, in Combination with Gemcitabine Plus nab-Paclitaxel in Previously Untreated Metastatic Pancreatic Cancer. *ESMO Open* 2025; 10(6):105122 PMID 40403387
  80. **Carneiro BA**, Gbolahan OB, Razak AAA, Hilton JF, Lambert AW, Hood J, Pluta M, Bragulat V, Sanai E, Kumar R, Jodrell DI, LoRusso PM. First-in-human study to evaluate the safety and efficacy of the anti-GDF15 antibody AZD8853 in patients with advanced/metastatic solid tumors. *Cancer Res Commun* 2025; 5(6):896-905 PMID 40354065
  81. Silverman IM, Schonhoft JD, Herzberg B, Yablonovitch A, Lagow E, Sethuraman S, Ulanet D, Yang J, Kim I, Basciano P, Cecchini M, Lee E, Lheureux S, Fontana E, **Carneiro BA**, Reis-Filho J, Yap TA, Zinda M, Rosen EY, Rimkunas V. Comprehensive baseline ctDNA characterization in two large pan-tumor phase I/II studies using genomic and methylation profiling. *Clin Cancer Res* 2025 In Press

## I. Reviews, editorials, and other peer-reviewed publications.

1. Ribeiro RA, **Carneiro-Filho BA**, Costa PFT. Cardiotoxicidade induzida por doxorubicina: patogênese e prevenção (Doxorubicin-induced cardiotoxicity: pathogenesis and prevention). *Revista da Sociedade Brasileira de Oncologia Clínica*, 1999; 1:21-30
2. **Carneiro-Filho BA**, Bushen OY, Brito GA, Lima AA, Guerrant RL. Glutamine analogues as adjunctive therapy for infectious diarrhea. *Current Infectious Diseases Reports* 2003; 5(2):114-119. PMID 12641996
3. Guerrant RL, **Carneiro-Filho BA**, Dillingham RA. Cholera, diarrhea and ORT: Triumph and indictment. *Clinical Infectious Diseases* 2003;37(1):398-405. PMID 12884165
4. Brito GA, Alcantara C, **Carneiro-Filho BA**, Guerrant RL. Pathophysiology and impact of enteric bacterial and protozoal infections: New approaches to therapy. *Chemotherapy* 2005; 51 Suppl 1:23-35. PMID 15855747

5. **Carneiro B**, Hsiao K, Khandekar J. Evolving molecular-based targeted therapy for cancer: an exciting field. *Comprehensive Therapy* 2005;31(4):299-305. PMID 16407611
6. **Carneiro BA**, Altman JK, Kaplan JB, Ossenkoppele G, Swords R, Plataniias LC, Giles FJ. Targeted therapy of acute myeloid leukemia. *Expert Rev Anticancer Ther* 2015; 15(4):399-413. PMID 25623136
7. Carneiro RM, **Carneiro BA**, Agulnik M, Kopp P, Giles FJ. Targeted therapies in advanced differentiated thyroid cancer. *Cancer Treat Rev* 2015; 41(8):690-8 PMID 26105190
8. **Carneiro BA**, Kaplan JB, Altman JK, Giles FJ, Plataniias LC. Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. *Cancer Biol Ther* 2015; 16(5):648-56 PMID 25801978
9. **Carneiro BA**, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. *Cancer Treat Rev* 2015; 41(2):170-8. PMID 25498841
10. **Carneiro BA**, Kaplan JB, Giles FJ. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events. *Exp Rev Hematol* 2015; 8(4):457-79 PMID 25938861.
11. Chae YK, Chung SY, Davis AA, **Carneiro BA**, Chandra S, Kaplan J, Kalyan A, Giles FJ. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. *Oncotarget* 2015; 6(35):37117-34. PMID 26359351.
12. Chae YK, Yousaf M, Malecek MK, **Carneiro B**, Chandra S, Kaplan J, Kalyan A, Sassano A, Plataniias LC, Giles F. Statins as anti-cancer therapy; can we translate preclinical and epidemiologic data into clinical benefit? *Discov Med* 2015; 20(112):413-27. PMID 26760985
13. Chae YK, Arya A, Malecek MK, Shin DS, **Carneiro B**, Chandra S, Kaplan J, Kalyan A, Altman J, Plataniias L, Giles F. Repurposing metformin for cancer treatment: current clinical studies. *Oncotarget* 2016; 7(26):40767-80. PMID 27004404
14. Costa R, **Carneiro BA**, Chandra S, Pai S, Chae YK, Kaplan JB, Garrett H, Agulnik M, Kopp PA, Giles FJ. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. *Drug Des Devel Ther* 2016; 10:873-84 PMID 27013865
15. Costa R, **Carneiro BA**, Tavora F, Pai SG, Kaplan JB, Chae YK, Chandra S, Kopp PA, Giles FJ. The challenge of developmental therapeutics for adrenocortical carcinoma. *Oncotarget* 2016; 7(29):46734-49. PMID 27102148
16. Costa R, **Carneiro BA**, Taxter T, Tavora F, Kalyan A, Pai S, Chae YK, Giles FG. FGFR3-TACC3 fusion in solid tumors-mini review. *Oncotarget* 2016; 7(34):55924-55938 PMID 27409839
17. **Carneiro BA**, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles F. Is personalized medicine here? *Oncology (Williston Park)* 2016; 30(4): 293-303; PMID 27085327
18. Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, **Carneiro B**, Villaflor VM, Cristofanilli M, Giles FJ. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. *Oncotarget* 2017; 8(9):16052-74 PMID 28030802
19. Costa R, Santa-Maria CA, Rossi G, **Carneiro BA**, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M. Developmental therapeutics for inflammatory breast cancer: biology and translational directions. *Oncotarget* 2017; 8(7): 12417-32 PMID 27926493
20. Walz A, Ugolkov A, Chandra S, Kozikowski A, **Carneiro BA**, O'Halloran TV, Giles FJ, Billadeau DD, Mazar AP. Molecular Pathways: Revisiting glycogen synthase kinase-3 $\beta$

- as a target for the treatment of cancer. *Clin Cancer Res* 2017; 23(8):1891-97 PMID 2805302
21. Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, **Carneiro BA**, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ. Targeting epidermal growth factor receptor in triple negative breast cancer: New discoveries and practical insights for drug development. *Cancer Treat Rev* 2017; 53:111-119 PMID 28104566
  22. Kalyan A, **Carneiro BA**, Chandra S, Kaplan JB, Chae YK, Matsangou M, Hendrix MJC, Giles FJ. Nodal signaling as a developmental therapeutics target in oncology. *Mol Cancer Ther* 2017; 16(5):787-92 PMID 28468864
  23. Costa R, **Carneiro BA**, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. *Ann Oncol* 2017; 28(1):44-56. PMID 28177431
  24. Chuzi S, Tavora F, Cruz M, Costa R, Chae Y, **Carneiro B**, Giles FJ. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. *Cancer Management and Research* 2017; 9:207-213 PMID 28652812
  25. Pai S, **Carneiro BA**, Mota JM, Costa R, Chae Y, Kaplan, J, Giles FJ. Wnt/beta-catenin pathway: modulating anti-cancer immune response. *Journal of Hematology & Oncology* 2017; 10(1):101 PMID 28476164
  26. Reinstein Z, Pamarthy S, Sagar V, Abdulkadir SA, Giles FJ, **Carneiro BA**. Overcoming immune suppression in bone metastases. *Critical Rev Oncology Hematology* 2017; 117:114-127 PMID 28600175
  27. Mota JM, Collier KA, Costa R, Taxter T, Chae Y, Giles FJ, **Carneiro BA**. A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer. *Oncotarget* 2017; 8(51):89284-06. PMID 286645115
  28. Chae YK, Pan AP, Davis AA, Patel SP, **Carneiro BA**, Kurzrock R, Giles FJ. Path towards precision oncology: review of targeted therapy studies and tools to aid in defining “actionability” of a molecular lesion and patient management support. *Mol Cancer Ther* 2017;16(12):2645-55 PMID 29203694
  29. Sahin I, Mega AE, **Carneiro BA**. Androgen receptor-independent prostate cancer: an emerging clinical entity. *Cancer Biol Ther* 2018; 15:1-2 PMID 29333925
  30. **Carneiro BA**, Dizon DS. Prostate cancer social media: in YouTube we trust? *European Urology* 2019; 75(4):568-569 PMID 30639141
  31. Sahin I, Eturi A, De Souza A, Pamarthy S, Tavora F, Giles FJ, **Carneiro BA**. Glycogen synthase kinase-3 beta (GSK-3 $\beta$ ) inhibitors as novel cancer treatments and modulators of anti-tumor immune responses. *Cancer Biol Ther* 2019; 20(8):1047-1056 PMID 30975030
  32. **Carneiro BA**, Lotan TL, De Souza A, Aggarwal R. Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer. *Am Soc Clin Oncol Educ Book* 2020; 40:3319-e332 PMID 32479115
  33. **Carneiro BA**, El-Deiry W. Targeting apoptosis in cancer therapy. *Nature Reviews Clinical Oncology* 2020; 17(7):395-417 PMID 32203277
  34. De Souza A, Tavora F, Mahalingam D, Munster P, Safran H, El-Deiry WS, **Carneiro BA**. Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response. *Front Immunol* 2020; 11:595289 PMID 33193448
  35. Prabhu VV, Morrow S, Kawakibi AR, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang W, Honeyman JN, Tavora F, **Carneiro B**, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L,

- Stogniew M, Allen JE, Oster W, El-Deiry WS. ONC201 and Imipridones: Anti-cancer Compounds with Clinical Efficacy. *Neoplasia* 2020; 22(12):725-744 PMID 33142238
36. George A, Sahin I, **Carneiro BA**, Dizon DS, Safran HP, El-Deiry WS. Strategies to sensitize cancer cells to immunotherapy. *Hum Vaccin Immunother* 2021; 21:1-7 PMID 34019474
  37. Soliman L, De Souza A, Srinivasan P, Danish M, Bertone P, El-Deiry WS, **Carneiro BA**. The role of BCL-2 proteins in the development of castration-resistant prostate cancer and emerging therapeutic strategies. *Am J Clin Oncol* 2021; 44(7):374-38 PMID 34014842
  38. Di Cristofano F, George A, Tajiknia V, Ghandali M, Wu L, Zhang Y, Srinivasan P, Strandberg J, Hahn M, Uruchurtu ASS, Seyhan AA, **Carneiro BA**, Zhou L, Huntington KE, El-Deiry WS. Therapeutic targeting of TRAIL death receptors. *Biochem Soc Trans* 2023 In Press PMID 36629496
  39. Cimadamore A, Franzese C, Di Loreto C, Blanca A, Lopez-Beltran A, Crestani A, Giannarini G, Tan PH, **Carneiro BA**, El-Deiry WS, Montironi R, Cheng L Predictive and prognostic biomarkers in urological tumours. *Pathology* 2024; 56(2):228-238 PMID 38199927
  40. Shi Y, Wang H, Golijanin B, Amin A, Lee J, Sikov M, Hyams E, Pareek G, **Carneiro BA**, Mega AE, Lagos GG, Wang L, Wang Z, Cheng L. Ductal, intraductal, and cribriform carcinoma of the prostate: molecular characteristics and clinical management. *Urol Oncol* 2024; 42(5):144-154 PMID 38485644
  41. Zhu L, Pan J, Mou W, Deng L, Zhu Y, Wang Y, Pareek G, Hyams E, **Carneiro BA**, Hadfield M, Tan T, Tong T, Ta N, Zhu Y, Gao Y, Cheng L, Chen R, Xue W. Harnessing Artificial Intelligence for Prostate Cancer Management. *Cell Rep Med* 2024;5(4):101506 PMID 38593808
  42. Tian X, Srinivasan PR, Tajiknia V, Uruchurtu A, Seyhan AA, **Carneiro BA**, De La Cruz A, Pinho-Schwermann M, George A, Zhao S, Strandberg J, Di Cristofano F, Zhang S, Zhoi L, Raufi A, Navaraj A, Zhang Y, Verovkina N, Ghandali M, Ryspayeva D, El-Deiry WS. Targeting apoptosis pathways for cancer therapy. *J Clin Invest* 2024; 134(14):e179570 PMID 39007268
  43. El-Deiry WS, Bresson C, Wunder F, **Carneiro BA**, Dizon DS, Warner JL, Graff SL, Azzoli CG et al. Worldwide innovative network (WIN) consortium in personalized cancer medicine: bringing next-generation precision oncology to patients. *Oncotarget* 2025;16:140-162 PMID 40073368
  44. Hadfield M, **Carneiro BA**, Cheng L. Targeted therapeutic approaches for the treatment of cancer: the future is bright. *J Pers Med* 2025; 15(4):141 PMID 40278320
  45. Stubbs NM, Roady TJ, Schwermann MP, Eteshola EO, MacDonald WJ, Purcell C, Ryspayeva D, Verovkina N, Tajiknia V, Ghandali M, Voong V, Lannigan AJ, Raufi AG, Lawler S, Holder SL, **Carneiro BA**, Cheng L, Safran HP, Graff SL, Dizon DS, Mani SA, Seyhan AA, Sobol RW, Wong ET, Chen CC, Gokaslan Z, Taylor MS, Rivers BM, El-Deiry WS. Acquired resistance to molecularly targeted therapies for cancer. *Cancer Drug Resist* 2025 PMID 40510029

## **BOOK CHAPTERS**

1. Medeiros FC, **Carneiro-Filho BA**, Ribeiro RA. Endometriose e dor pélvica crônica (Endometriosis and chronic pelvic pain). In: Tópicos Seleccionados em Medicina



- Reprodutiva, pp 173-180. Eds: Medeiros FC, Hypolito S, Medeiros M, PrintColor Ed, Fortaleza, 2003
2. **Carneiro BA**, Bahary N. Principles of Chemotherapy. In: Surgical Oncology: Fundamentals, Evidence-based Approaches and New Technology, David L Bartlett, Pragatheeshwar Thirunavukarasu, Matthew D Neal (Ed), Jaypee Brothers Medical Publishers, 2011
  3. **Carneiro BA**, Brockstein BE, Kerstin SM, Song S. Overview of treatment for squamous cell head and neck cancer. In: UpToDate, Rose BD (Ed), UpToDate, Wellesley, MA, 2013.
  4. Quitude ARP, **Carneiro BA**. Tumores neuroendocrinos gastroenteropancreaticos. In: Gastroenterologia e Hepatologia – Sinais, Sintomas, Diagnostico e Tratamento. Jose Milton C Lima, Jesus I da Costa, Armenio A Santos, Edicoes UFC, Fortaleza, CE, Brazil, 2019.
  5. De Souza A, **Carneiro B**, Mega A, Gilligan T. Genitourinary tumors. In: Cecil Essentials of Medicine (10<sup>th</sup> edition), Edward J Wing, Fred Schiffman (Ed), 2020.
  6. De Souza A, Lagos G, Mega A, **Carneiro B**. Genitourinary tumors. In: Cecil Essentials of Medicine (11<sup>th</sup> edition), Edward J Wing, Fred Schiffman (Ed), 2024.

#### **PUBLICATIONS SUBMITTED OR IN PREPARATION**

1. De Souza AL, Hadfield MJ, Lu S, Golijanin DJ, Wood R, Margolis J, Anderson K, Olszewski AJ, Holder SL, El-Deiry WS, Aggarwal RR, Mega AE, **Carneiro BA**. BrUOG360: A phase Ib/II study of copanlisib in combination with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). Submitted to *Clin Cancer Res*
2. **Carneiro BA**, Marron T, Zamarin D, Castañón E, Patel SP, Subbiah V, Mehmi I, El-Khoueiry A, Oberoi A, Abadier M, Jennings E, Elgeioushi N, Durham NM, Ridgway B, Fraenkel PG, Azaro A, Hamid O. Safety and efficacy of intratumoral MEDI1191 (IL-12 mRNA) in combination with intravenous durvalumab in previously treated patients with advanced solid tumors: first-in-human study. Submitted to Clin Cancer Research
3. Powderly J, Imbimbo M, Italiano A, Romano P, McKean M, Macarulla T, Alvarez EC, **Carneiro BA**, Mager R, Barnhart V, Eck S, Murtomaki E, Loembé A, He Y, Cooper ZA, Tu E, Fan C, Chamard AB, Paturel C, Fraenkel PG, Hollebecque A. IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors. Submitted to Clin Cancer Research
4. Lin C, Hadfield M, Santopietro A, Lagos G, Cheng L, El-Deiry WS, Aggarwal R, Mega A, **Carneiro BA**. The Evolving Landscape of Antibody-Drug Conjugates (ADCs) for treatment of Prostate Cancer. Submitted to NPJ Precision Oncology
5. Yap TA, Fontana E, Lee EK, Mahalingham D, Højgaard M, Mettu NB, Cote GM, Plummer R, Koehler M, Ulanet DB, Fei K, Silverman IM, Schonhoft JD, Rimkunas V, Bacque ES, Gomez G, Fretland AJ, Roulston A, Li L, Baruah P, Zimmermann M, Yang J, **Carneiro BA**, Lheureux S. Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results.
6. Tavora FT, Borden B, Lotan T, Zhou L, Amin A, Arunasalam N, De Souza A, Mega A, Golijanin D, Mazar A, Giles F, El-Deiry WS, **Carneiro BA**. GSK-3 $\beta$  as a potential target in prostate cancer, and correlation with PTEN loss and ERG status. In preparation.

## **ABSTRACTS (since 2017)**

1. Zhang Q, Kuzel T, Helfand B, Yang XJ, Qin W, Lee C, **Carneiro B**, Giles FJ. TGF- $\beta$  insensitive PSMA-specific CD8+ T cells derived from metastatic castration resistant prostate cancer (MCRPC) patients enhance the tumor killing ability. American Association for Cancer Research (AACR) Annual Meeting 2017 (abstract 5585/17)
2. Pamarthy S, Sagar V, Vatapalli RJ, Reinstein Z, Ansari MZ, **Carneiro BA**, Giles FJ, Abdulkadir SA. Combining anti-androgen therapy and PARP inhibition results in synergistic cytotoxicity of metastatic castration-resistant prostate cancer (mCRPC) cells. AACR Annual Meeting 2017 (abstract 1114/7)
3. Reinstein Z, Vatapalli R, Anker J, Pamarthy S, **Carneiro B**, Abdulkadir S. Talazoparib, a second-generation PARP inhibitor, is a novel therapy for PTEN mutants in prostate cancer. AACR Annual Meeting 2017 (abstract 1230/15)
4. Pai S, **Carneiro B**, Kalyan A, Costa R, Helenowski I, Radmeaker A, Shah H, Olson D, Chae Y, Giles F. Correlation of tumor mutation burden and chemotherapy outcomes in colorectal cancer. AACR Annual Meeting 2017 (abstract 2771/3)
5. Meeks J, **Carneiro BA**, Pai SG, Oberlin D, Rademaker A, Fedorchak K, Balasubramanian S, Elvin JA, Beaubier N, Giles FJ. Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer. 2017 Genitourinary Cancers Symposium. ASCO Annual Meeting 2017; J Clin Oncol 35, 2017 (suppl 6S; abstract 397)
6. Cavalcante L, **Carneiro BA**, Costa R, Chae YK, Rademaker A, Giles FJ. Preliminary results from a phase II study of nivolumab for patients with metastatic adrenocortical carcinoma (ACC). 2017 ASCO-SITC Clinical Immuno-Oncology Symposium J Clin Oncol 35, 2017 (suppl 7S; abstract 96)

## **2018**

7. Bardia A, Rich TA, Raymond VM, Sartor O, Lilly MB, Nezami MA, Patel S, **Carneiro BA**, Wang G, Fan A, Brufsky AM, Parker BA, Bridges BB, Lanman RB, Cristofanilli M. Landscape of *BRCA1* and *BRCA2* germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer. ASCO Annual Meeting 2018; J Clin Oncol 36, 2018 (suppl; abstr 12097)
8. Chanza NM, Bosse D, Bilen MA, Geynisman D, Balakrishnan A, Jain R, Bowman I, Zakharia Y, Narayan V, Beuselinck B, Agarawal N, McKay R, Hsu J, Shah S, Tripathi A, Lam E, Rose T, **Carneiro B**, Vogelzang N, Harshman L. Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis. American Society of Clinical Oncology (ASCO) Annual Meeting 2018; J Clin Oncol 36, 2018 (suppl; abstr 4579)
9. Wei XX, McKay RR, Gray KP, Stadler W, McDermott DF, McGregor BA, Agarwal N, Kyriakopoulos C, **Carneiro B**, Rose T, Zakaria Y, Braun D, Van Allen EM, Signoretti S, Choueiri TK, Harshman LC. Optimized Management of Nivolumab (NIVO) and Ipilimumab (IPI) in Advanced Renal Cell Carcinoma (OMNIVORE): A Response-Based Phase II Study. American Society of Clinical Oncology (ASCO) Annual Meeting 2018; J Clin Oncol 36, 2018 (suppl; abstr TPS4600)
10. Lewis C, Smith DC, **Carneiro BA**, Ryan CJ, Rodvelt TJ, Lee M, Friedlander TW, Lin AM, Kim W, Miralda B, Campbell G, Aggarwal RR. c15-149: A Phase 1b Study of the Oral CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer (mCRPC): a Prostate Cancer Clinical Trials Consortium Study. American Society of Clinical Oncology (ASCO) Annual Meeting 2018; J Clin Oncol 36, 2018 (suppl; abstr e17028)

11. Da Silva AVA, Tavora F, Neto FM, Oliveira ACDS, Alves M, **Carneiro B**, Lima AM. PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients from Brazil. *Journal of Thoracic Oncology* 2018; 13(10):S1020 (abstract)
12. Vatapalli R, Rodriguez Y, Zhao C, Sagar V, Anker J, Pamarthi S, Unno S, **Carneiro B**, Chakravarti D, Abdulkadir S. Dot-1L inhibition selectively impairs androgen receptor dependent prostate cancer growth through loss of telomere integrity. AACR Annual Meeting 2018 Abstract 3687
13. Zhang Q, Helfand B, Yang X, **Carneiro B**, Giles FJ, Kuzel T, Lee C, Cristofanilli M. PSMA-specific, TGF- $\beta$ -insensitive CD8<sup>+</sup> T cells derived from metastatic castration resistant prostate cancer (mCRPC) patients induce apoptosis of PSMA positive prostate cancer (PCa). AACR Annual Meeting 2018 Abstract 2553

#### 2019

14. **Carneiro BA**, Dhawan M, Borden B, Cavalcante L, Safran H, Ugolkov A, Mazar AP, Billadeau DD, Giles FJ, Munster P. GSK-3 $\beta$  blockade with 9-ING-41 in pancreas cancer: The 1801 Phase 1/2 study. AACR Conference – Pancreatic Cancer: Advances in Science and Clinical Care September, 2019
15. **Carneiro BA**, Cavalcante L, Munster P, De Souza A, Safran H, Giles FJ. Phase 1/2 Study of 9-ING-41, a small molecule selective Glycogen Synthase Kinase-3 Beta (GSK-3 $\beta$ ) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors. European Society of Medical Oncology (ESMO) Congress; *Annals of Oncology* 30(suppl 5) 2019
16. Cho M, Bendell J, Han S-W, Naidoo J, Lieu C, **Carneiro B**, Varga E, Li X, Kourtesis P, Abdullah S, Patel S. Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC). European Society of Medical Oncology (ESMO) Congress 2019; *Ann Oncol* 2019; 30(suppl 5):v475-532
17. Tran B, Voskoboynik M, Bendell J, Gutierrez M, Lemech C, Day D, Frentzas S, Garrido-Laguna I, DelNagro C, Wang F, Das M, **Carneiro B**. First-in-human study of CD40 agonist MEDI5083 alone and in combination with durvalumab in advanced solid tumors. Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 2019.
18. de Jonge MJA, **Carneiro BA**, Devriese L, Doi T, Penugonda S, Petrich AM, Nuthalapati S, Motwani M, Modi D, Chang Y, Calvo E, Moreno V. First-in-Human Study of ABBV-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology meeting 2019.
19. Borden B, Crawford L, Safran HP, Giles FJ, El-Deiry WS, **Carneiro BA**. Assessment of Glycogen synthase kinase-3 beta (GSK3b) Genomic Landscape to Inform Use of Cancer Therapeutics. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. October, 2019.

#### 2020

20. Duarte C, Martinez Chanza N, Collier K, Dizman N, Rath N, McKay RR, Panian J, Narayan V, **Carneiro BA**, Mega AE, Hu J, Meguid C, Agarwal N, Pal SK, Mortazavi A, Harshman LC, Lam ET. Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC). ASCO Genitourinary Cancers Symposium; *Journal of Clinical Oncology* 38, no. 6\_suppl (February 20, 2020) 681
21. Marron T, Subbiah V, Hamid O, Goel S, Hellmann MD, **Carneiro BA**, El-Khoueiry A, Patel SP, de Vries E, Luheshi N, Hamid O, Gascó Hernández A. MEDI1191, a novel IL-

- 12 mRNA therapy for intratumoral injection to promote T<sub>H</sub>1 transformation of the tumor microenvironment. ESMO 2020; Ann Oncol 2020; 31(suppl 4): S730
22. Powderly J, Bendell JC, **Carneiro BA**, Italiano A, Mercadé TM, Alvarez EC, Imbimbo M, Massard C, Mueller NK, Gascó Hernández A. A Phase 1, First-in-Human, Multicenter, Open-Label, Dose-Escalation Study of IPH5201 as Monotherapy or in Combination With Durvalumab ± Oleclumab in Advanced Solid Tumors. ESMO 2020; Ann Oncol 2020; 31(suppl 4):S645-6717
  23. Tavora F, Zhou L, Amin A, Howard S, Arunasalam N, de Souza A, Mega A, Golijanin D, El-Deiry S, **Carneiro B**. ONC201 shows synergistic effect with the androgen receptor AR-inhibitor darotutamide in prostate cancer models. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1836
  24. Tavora F, Lotan T, Alves M, Zhou L, Amin A, Arunasalam N, De Souza A, Mega A, Golijanin D, Giles F, El-Deiry W, **Carneiro B**. Glycogen synthase kinase 3-β expression in prostate cancer (PCa) correlates with aggressive pathological features and its blockade with 9-ING-41 inhibits viability of PCa cell lines. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2959.
  25. Borden BA, Xiu J, Baca Y, Ramos P, Giles FJ, Mazar A, Tavora F, Safran H, El-Deiry WS, **Carneiro BA**. Glycogen synthase kinase-3 beta (GSK-3b) genomic alterations and increased programmed death-ligand 1 (PD-L1) expression in advanced malignancies. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5292.
  26. Henrich SE, McMahon K, Plebanek M, Tavora F, De Souza A, Mega A, **Carneiro BA**, Thaxton CS. Prostate cancer exosomes alter extracellular matrix composition in bone marrow and enhance metastasis. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6204.
  27. **Carneiro BA**, Bestvina CM, Shacham-Shmueli, E, Gan HK, Beck, JT, Robinson, R, Fischer, J, Wong, A, Ansell, P, Jin, J, Naumovski, L, Papadopoulos, KP. Phase 1 study of the antibody-drug conjugate ABBV-321 in patients with non-small cell lung cancer and squamous head and neck cancer with overexpression of the epidermal growth factor receptor. ASCO Annual Meeting; *Journal of Clinical Oncology* 38:2020 (suppl; abstr TPS3649)
  28. **Carneiro BA**, Cavalcante L, Bastos BR, Powell SF, Ma WW, Sahebjam S, Harvey D, De Souza AL, Dhawan M, Safran H, Giles FJ, Munster, PN. Phase I study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. *J Clin Oncol* 38 (suppl; abstr 3507). **Oral presentation at the Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

## 2021

29. Hamid O, Hellmann MD, **Carneiro BA**, Marron T, Subbiah V, Inderjit M, Eyles J, Dubois V, Ridgway B, Hamid O, Hernández AG. Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumors and superficial lesions. Proffered Paper at ESMO Targeted Anticancer Therapies Congress 2021.

30. De Souza A, Aggarwal R, Safran H, Golijanin D, Wood R, Olszewski A, El-Deiry WS, Mega A, **Carneiro BA**. BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). AACR Annual Meeting 2021. *Cancer Res* 2021;81(13 suppl):CT222
31. Soliman L, De Souza A, Srinivasan P, Danish M, Golijanin D, Amin A, Mega A, El-Deiry W, Bertone P, **Carneiro BA**. Differential transcriptomic profiling of primary tumors and metastatic sites in advanced prostate cancer. AACR Annual Meeting 2021. *Cancer Res* 2021;81(13 suppl):2195
32. De Souza A, Srinivasan P, Soliman L, Golijanin D, Amin A, Safran H, Mega A, El-Deiry WS, **Carneiro BA**. Clinical and genomic features of advanced urothelial carcinoma with 9p21 deletion. AACR Annual Meeting 2021. *Cancer Res* 2021;81(13 suppl):1205
33. Huntington KE, Zhang S, Campbell K, **Carneiro BA**, El-Deiry WS. GSK3 $\beta$  inhibition by small molecule 9-ING-41 decreases VEGF and other cytokines, and boosts NK and T cell-mediated killing of colorectal tumor cells. AACR Annual Meeting 2021. *Cancer Res* 2021;81(13 suppl):2676
34. Tolcher AW, **Carneiro BA**, Dowlati A, Razak AR, Chae YK, Villella JA, Coppola S, Englert S, Phillips AC, Souers AJ, Salman Z, Penugonda S, Powderly II JD, LoRusso P. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. ASCO Annual Meeting 2021. *J Clin Oncol* 2021; 39 (15 suppl):3015
35. Odia Y, Cavalcante L, Safran H, Powell SF, Munster PN, Ma WW, **Carneiro BA**, Bastos BR, Giles FJ, Sahebjam S. Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3 $\beta$ ) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors. ASCO Annual Meeting 2021. *J Clin Oncol* 2021; 39 (15 suppl):2051
36. Kouchkovsky I, Rao A, **Carneiro BA**, Zhang L, Lewis C, Phone A, Small EJ, Friedlander TW, Fong L, Paris P, Ryan CJ, Szumulewitz RZ, Aggarwal RR. A phase (Ph) 1b/2 study of ribociclib (R in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). ASCO Annual Meeting 2021. *J Clin Oncol* 2021; 39 (15 suppl):5043
37. **Carneiro BA**, Yin J, Soliman L, De Souza A, Golijanin D, Mega A, Barata PC, Gulati S, Wei S, Geynisman DM, Magee D, Korn WM, Abuali I, Heath EI, Ryan C, Bertone P, El-Deiry WS. Differential transcriptomic profiling of BCL2-related genes in primary tumor and metastatic sites of prostate cancer (PCa), ESMO 2021. *Ann Oncol* 2021;32(suppl 5):S626-S677
38. **Carneiro B**, Mahalingam D, Safran H, Powell SF, Coveler AL, Davis EJ, Cervantes A, Sahai V, Steeghs N, Alvaro MH, Schuller Y, Berlin J, Mulcahy M, Giles FJ, Cavalcante L, Saeed A. Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3 $\beta$ ) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC): Interim Results. ESMO 2021
39. **Carneiro BA**, Jotte R, Gabrail N, Hamid O, Huang F, Chaturvedi S, Herpers M, Soler LM, Childs BH, Hansen A. Safety and efficacy of copanlisib in combination with nivolumab: a Phase Ib study in patients with advanced solid tumors. Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; *Mol Cancer Ther* 2021;20(12 Suppl):Abstract nr P239
40. Borden BA, De Souza A, Mahalingam D, Powell S, Munster PN, Huntington K, Mazar A, Cavalcante L, Giles FJ, El-Deiry WS, Safran HP, **Carneiro BA**. Genomic Biomarkers

for Response to 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3) inhibitor, in Pancreas Cancer: preliminary results. Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P021.

## 2022

41. **Carneiro BA**, DeSouza A, Golijanin D, Wood R, Olszewski AJ, Holder SL, El-Deiry WS, Aggarwal RA, Mega AE. BrUOG360: A Phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ASCO Genitourinary Cancer Symposium 2022; Abstract 357963
42. Huang KM, Boehm N, Gan HK, **Carneiro BA**, Robinson RR, Aristide MN, Alturi H, RM Menon. Pharmacokinetics and exposure-response analysis of ABBV-321, an EGFR-targeting ADC, in patients with advanced solid tumors. American Society for Clinical Pharmacology and Therapeutics Annual Meeting 2022
43. El-Deiry WS, Arnoff T, Sahin I, Khatri I, Lou E, Liu SV, Borghaei H, Plimack E, Subbiah V, Khan H, **Carneiro BA**, Safran H, Graff S, Dizon D, Heath E, Wong E, George A, Hahn M, Chang WI, Raufi A, DeSouza A, Abbas A, Azzoli C, Demeure M, Marshall J, Lenz HJ, Doebele RC, Abraham J, Kurzrock R, Xiu J. Impact of MDM2/MDM4 (MDMX) on immune checkpoint blockade (ICB) treatment outcomes in advanced cancer. American Society of Clinical Oncology Annual Meeting 2022
44. Darabi S, Braxton DR, Xiu J, **Carneiro B**, Swensen J, Antorakis E, Liu S, McKay R, Spetzler D, El-Deiry WS, Demeure MJ. Reversion Mutations in *BRCA1* or *BRCA2* genes: Resistant Mechanism(s) in Patients treated with Platinum-Based Agents or Poly (ADP-ribose) polymerase (PARP) Inhibitors. American Society of Clinical Oncology Annual Meeting 2022
45. Le X, **Carneiro BA**, Hong DS, Taylor M, Patel SA, William WN, Wang B, Beca F, Jain S, Soumaoro I, Dunn L. innovaTV 207: New Combination Dosing Cohorts in the Open Label Phase 2 Study of Tisotumab Vedotin in Solid Tumors. American Society of Clinical Oncology Annual Meeting 2022
46. Rotow, J, Yoh K, Powderly J, Shimizu T, Perets R, Paz-Ares L, Phillips A, Souers A, Ansell P, Jin J, Badawi M, Saab R, Morrison-Thiele G, Jeffries S, Neagu Aristide M, **Carneiro B**, Papadopoulos KP. First-in-human phase 1 study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors. American Society of Clinical Oncology Annual Meeting 2022
47. Rosen E, Silverman I, Fontana E, Lee E, Spigel D, Højgaard M, Lheureux S, Mettu N, **Carneiro BA**, Carter L, Plummer R, Schonhoft JD, Ulanet D, Manley P, Reis-Filho JS, Xu Y, Rimkunas V, Koehler M, Yap TA. Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial. American Society of Clinical Oncology Annual Meeting 2022.
48. Hwang J, McGrath J, Lozada JR, Brodskiy P, Xiu J, Wei S, Heath E, **Carneiro BA**, Lou E, Soares H, McKay RR, Antonarakis ES, Ryan C, Spetzler D, Beltran H. Molecular correlates of Delta-like-ligand 3 (DLL3) expression in neuroendocrine cancers (NCs). American Society of Clinical Oncology Annual Meeting 2022.
49. El-Deiry WS, Arnoff T, **Carneiro B**, DeSouza A, Amin A, Safran H, Heath E, Joshi M, Plimack E, Golijanin D, Holder S, Mega A, Khushman M, Darabi S, Antonarakis E, Saeed A, Lou E, Korn M, Xiu J, Yin J. Concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer show distinct genomic and immunological



- profiles suggestive of therapeutic strategies. American Society of Clinical Oncology Annual Meeting 2022.
50. Yap TA, Silverman IM, Fontana E, Lee E, Spigel D, Højgaard M, Lheureux S, Mettu N, **Carneiro BA**, Carter L, Plummer R, Schonhofs JD, Ulanet D, Nejad P, Manley P, Reis-Filho JS, Xu Y, Rimkunas V, Koehler M, Rosen E. Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial. American Association for Cancer Research Annual Meeting 2022.
  51. **Carneiro BA**, Zamarin D, Marron T, Inderjit M, Patel SP, Subbiah V, El-Khoueiry A, Grand D, Garcia-Reyes K, Goel S, Martin P, Wang J, Wu Y, Eck S, Ridgway B, Elgeioushi N, Eyles J, Durham J, Azaro A, Hamid O. First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors. American Association for Cancer Research Annual Meeting 2022.
  52. Sanborn R, Gabrail N, **Carneiro BA**, O'Hara M, Bordoni R, Gordon M, Khalil D, Hauke R, Taglienti C, Rogalski M, Styles R, Alvarado D, Maurer D, Crew L, Keler T, Yellin M. Results from a Phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab. SITC 37<sup>th</sup> Annual Meeting, 2022, Abstract 214577
  53. Abadier M, Jennings E, Eyles J, Martin P, Pilataxi F, Wu Y, Chen X, Azaro A, Ridgway B, Philips M, Chandrasekar P, **Carneiro BA**, Hamid O, Marron T, Zamarin D, Castañón E, Patel S, Garralda E, Subbiah V, El-Khoueiry A, Fraenkel PG, Durham N. MEDI1191 (IL-12 mRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (C/SC) lesions. SITC 37<sup>th</sup> Annual Meeting, 2022.
  54. Rotow J, Yoh K, Powderly J, Shimizu T, Perets R, Paz-Ares L, Phillips A, Souers A, Ansell P, Jin J, Badawi M, Saab R, Morrison-Thiele G, Jeffries S, Neagu Aristide M, **Carneiro B**, Papadopoulos K. First-in-human phase 1 study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors. ESMO Annual Meeting 2022

## 2023

55. **Carneiro BA**, Perets R, Dowlati A, LoRusso P, Yonemori K, He L, Munasinghe W, Noorani B, Johnson EF, Zugazagoitia J. Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results. American Society of Clinical Oncology Annual Meeting 2023. J Clin Oncol 41, 2023 (suppl 16; abstr 3027)
56. **Carneiro BA**, Safran HP, Beck JT, Hamid O, Spira A, Savvides P, Gutierrez M, Zhao Y, Abbruzzese J, Ward JP, Weroha SJ, Harris L, Kent S, Pierceall W, Skoura A, Zheng J, Kern KA, Thomas JS, Santana-Davila R. Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors. American Society of Clinical Oncology Annual Meeting 2023. J Clin Oncol 41, 2023 (suppl 16; abstr 2529)
57. Mahalingam D, Saeed A, Powell SF, Alvaro MH, Sahai V, Coveler AL, Davis EJ, Steeghs N, Mulcahy MF, Raufi AG, Cavalcante L, Cervantes A, Berlin J, Afanasjeva J, Mikrut W, Smith SL, Giles FJ, **Carneiro BA**. Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC). American Society of Clinical Oncology Annual Meeting 2023. J Clin Oncol 41, 2023 (suppl 16; abstr e16289)

58. Schwermann M, Tajiknia V, Zhou L, George A, Srinivasan P, De Souza A, Mega AE, Safran H, **Carneiro BA**, El-Deiry WS. Androgen receptor inhibitors and anti-NKG2A checkpoint inhibitor to enhance NK cell-mediated killing of prostate cancer cell lines in vitro. American Society of Clinical Oncology Annual Meeting 2023. J Clin Oncol 41, 2023 (suppl 16; abstr e17066).
59. McDermott J, Weiskittel T, Borden B, Cavalcante L, Giles FJ, **Carneiro BA**, Li H, Mazar AP. In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors. American Society of Clinical Oncology Annual Meeting 2023. J Clin Oncol 41, 2023 (suppl 16; abstr 3079).
60. Weiskittel T, Huntington K, **Carneiro BA**, Cavalcante L, Mahalingam D, Giles FJ, Munster PN, El-Deiry WS, Li H, Mazar AP. Plasma cytokine profiles and survival outcomes in the 1801 phase 1/2 clinical trial of 9-ING-41 (elraglusib) in patients with advanced cancer. American Society of Clinical Oncology Annual Meeting 2023. J Clin Oncol 41, 2023 (suppl 16; abstr e14555).
61. El-Deiry WS, Huntington K, Louie A, Srinivasan P, Schorl C, Lu S, Silverberg D, Newhouse D, Wu Z, Zhou L, Ryspayeva D, Borden B, Giles FJ, Dooner M, **Carneiro BA**. GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer. American Society of Clinical Oncology Annual Meeting 2023. J Clin Oncol 41, 2023 (suppl 16; abstr e15138).
62. Carlsen L, Elliott A, Capelletti M, Lou E, Marshall J, Lenz HJ, Philip PA, Hall MJ, Sledge GW, Raufi AG, Breakstone R, Almhanna K, **Carneiro BA**, Safran H, El-Deiry WS. Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients. American Society of Clinical Oncology Annual Meeting 2023. J Clin Oncol 41, 2023 (suppl 16; abstr 3526).
63. Moon J, Ryu S, Ramos I, Garmezy B, Hamm J, **Carneiro B**, Wise-Draper T, Wilky B, Sanborn R, El-Khoueiry A, Purbhoo M, Hoon D, Van Dijk M. Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer. Society for Immunotherapy of Cancer Annual Meeting 2023 Abstract 735
64. Wilks S, **Carneiro B**, Cote G, Henry J, Sen S, Spira A, Tsai F, Wang J, Crochiere M, He S, Smyrniotis S, Unadkat D, Zhang B, Tolcher A. A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors. Society for Immunotherapy of Cancer Annual Meeting 2023 Abstract 762
65. Abadier M, Chow J, Van L, Sehgal V, Feldman I, Do K, Aanur P, Durham N, Chen X, Wu Y, Fraenkel P, Azaro A, Castanon Alvarez E, Zamarin D, **Carneiro B**, Marron T, Patel S, Subbiah V, Mehmi I, Oberoi A, El-Khoueiry A, Hamid O. Intratumoral mRNA IL-12 can induce a dose dependent immunostimulatory effect within tumor microenvironment in patients with advanced solid tumors. Society for Immunotherapy of Cancer Annual Meeting 2023 Abstract 1043
66. Voss M, Garmezy B, Kim SH, Maroto P, Mansinho A, Rodriguez-Vida A, Oliveira J, van Dongen M, Rodriguez LM, Negrier S, Tran B, **Carneiro BA**, Castanon Alvarez E, Rha SY, Wang Y, Gainer SD, Tang Z, Achour I, Asare JM, Albiges L. MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of patients (pts) with advanced clear cell renal cell carcinoma (aRCC). ESMO 2023 Presentation 1883MO
67. **Carneiro BA**, Garmezy B, Hamm JT, Sanborn R, Wise-Draper T, El-Khoueiry A, Wilky B, Hoon D, Buffa A, Michelet X, Purbhoo MA, Exley MA, Einstein D. Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or



- in combination with pembrolizumab or nivolumab in patients with advanced solid tumors. AACR 2023
68. Hadfield MJ, DeSouza A, Golijanin D, Wood R, Olszewski A, Holder S, El-Deiry WS, Aggarwal RR, Mega AE, **Carneiro BA**. BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). AACR 2023.
  69. LoRusso P, Calvo E, Yamamoto N, Lin C, Beck J, Sommerhalder D, Oh D, Powderly JD, Golan T, Abraham L, Hayflick JS, Uziel T, Brunsdon P, Munasinghe W, Paddock M, Hartman C, Powell J, Medeiros B, Neagu MR, **Carneiro BA**. First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors. AACR 2023.
  70. Weiskittel T, McDermott J, Billadeau D, Li H, Saeed A, Mahalingam D, Sahebjam S, Munster P, Cavalcante L, Giles FJ, Mazar A, **Carneiro BA**. Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial. AACR 2023
  71. De Souza A, Mega A, Safran H, Amin A, Cheng L, Golijanin D, Holder S, Lagos G, El-Deiry WS, **Carneiro BA**. Tissue-based next generation sequence is more accurate than ctDNA to detected driver and actionable mutations in MTAP wild type tumors. AACR 2023.
  72. Castañón E, Zamarin D, **Carneiro B**, Marron T, Patel S, Subbiah V, Mehmi I, Oberoi H, El-Khoueiry A, Ridgway B, Elgeioushi N, Durham NM, Jennings E, Abadier M, Fraenkel P, Azaro A, Hamid O. Intratumoral (IT) MEDI1191 plus durvalumab (D): Update on the first-in-human study in advanced solid tumors. AACR 2023.
  73. Yap T, Yadav S, Herzberg B, **Carneiro BA**, Fontana E, Højgaard M, Pishvaian M, Plummer R, Werner T, Sahai V, Lheureux S, Lee E, Mettu E, Cote G, Schonhoft J, Rimkunas V, Silverman I, Wainszelbaum R, Peltz R, Fretland A, Fei K, Ulanet D, Kim I, Koehler M, Rosen E, Cecchini M. Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations. AACR 2023
  74. Huntington K, Schorl C, Lu S, **Carneiro BA**, El-Deiry WS. Multiplex digital spatial profiling of proteins in the tumor microenvironment in response to GSK-3 inhibition by 9-ING-41 (elraglusib) correlates with novel immunostimulatory effects observed *in vivo*
  75. Cavalcante L, Deshmukh S, **Carneiro BA**, Angara K, Mattox T, Wu S, Xiu J, Walker P, Oberley M, Nabhan C, Antonarakis E. Opposing roles of SPOP mutations in human prostate and endometrial cancers. AACR 2023
  76. El-Deiry WS, George A, Di Cristofano F, Srinivasan P, Carlsen L, Huntington K, De La Cruz A, Zhang L, Hahn M, Zhao S, Seyhan A, Denardo B, Maxwell A, Kim D, Raufi A, Khan H, Graff S, Dizon D, Azzoli C, Abbas A, Wood R, Lulla R, Safran H, **Carneiro BA**, Navaraj A, Tian X, Zhang S, Zhou L. Inclusive basic and advanced translational laboratory research competencies for research in cancer biology and therapeutics. AACR 2023.
  77. Zhou L, Zhang S, Huntington K, **Carneiro BA**, El-Deiry WS. Heterogeneity of cytokine secretion in single senescent fibroblasts is impacted by ONC201 and ABT-263. AACR 2023.

## 2024

78. **Carneiro BA**, Gbolahan O, Razak AA, Hilton JF, Lambert A, Hood J, Pluta M, Bragulat V, Sanai E, Kumar R, Jodrell D, LoRusso P. Safety and efficacy of AZD8853, an anti-

- growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors: First-in-human study. AACR 2024
79. Yamamoto N, Doi T, Patel MR, Garrido-Laguna I, Wu S, Nishioka S, Nakajima K, **Carneiro BA**. A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1. AACR 2024
  80. Schwermann M, Hadfield M, Lu S, Srinivasan P, Tajiknia V, MacDonald V, George A, Zhang S, Zhang L, Meza KS, De Souza A, Golijanin D, Hyams E, Lagos G, Holder S, Mega A, Sedivy J, Safran H, El-Deiry W, **Carneiro B**. Androgen deprivation therapy (ADT) and senescence-associated secretory phenotype (SASP) in vitro: Correlation with SASP in tumor specimens as well as in the serum of patients after ADT. AACR 2024.
  81. Schwermann M, Srinivasan P, MacDonald W, Tajiknia V, Schmidt A, Zhang S, Carlsen L, George A, Purcell C, Lu S, Hadfield M, Mega A, **Carneiro B**, El-Deiry W. TRAIL-NK-92 MI as a novel adoptive therapy for castration-resistant prostate cancer (CRPC): preliminary *in vitro* results. AACR 2024.
  82. Schwermann M, **Carneiro B**, Lu S, De Souza A, Hadfield M, Mega A, Lagos G, Khaleel S, Golijanin D, Holder S, Srinivasan P, MacDonald W, George A, Zhou L, Zhang L, El-Deiry W. Patient-derived MTAP-deleted bladder cancer organoid model: a unique platform for drug development. AACR 2024.
  83. Holder S, Lagos G, **Carneiro BA**, Mega A, De Souza A, McKay RR, Elliott A, Nabhan C, Graff SL. An analysis of proviral insertion site of Moloney murine leukemia virus, PIM1, kinase expression and clinical outcomes in renal cell carcinoma. AACR 2024.
  84. Araoye M, Mega A, Lagos G, **Carneiro B**, Khaleel S, Golijanin D, Holder S. Targeting androgen signaling in urothelial carcinoma. AACR 2024.
  85. Weiskittel T, Huntington K, Zhang L, Koukol A, **Carneiro BA**, Li H, Ugolkov A, El-Deiry W, Mazar A. Identification of potential immune biomarkers for GSK-3 inhibitor elraglusib (9-ING-41) in patients with relapsed/refractory metastatic cancer. AACR 2024.
  86. Ghandali M, Srinivasan P, Xia Y, Wong ET, Sobol RW, Zhou L, **Carneiro BA**, Graff SL, El-Deiry WS. Tumor Treating Fields (TTFields) show efficacy in Triple-Negative breast cancer (TNBC) cells alone and in combination with PARP inhibitor Talazoparib. AACR 2024.
  87. **Carneiro BA**, McKean M, Vicier C, Valerin JB, Tarhini A, Ganju V, Ruisi M, Kirby P, Cuillerot JM, Romano E. A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2R $\alpha$ -active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors. ASCO Annual Meeting 2024 J Clin Oncol 42, 2024 (suppl 16; abstr TPS2704).
  88. Spigel D, Ahn M, Majem M, Medina-Rodríguez L, Lee K, Carcereny E, Hernández AA, Insa A, Cho E, Besse B, Rha S, Weiss J, D'Arcangelo M, Im S, Kim S, **Carneiro BA**, Gadgeel SM, Mitchell P, Asare JM, Gainer S, Achour I, Subramaniam DS, Felip E. Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update. World Conference on Lung Cancer, September 7<sup>th</sup>, 2024.
  89. **Carneiro BA**, Rosen E, Fontana E, Lee EK, Mettu NB, Lheureux S, Silverman IM, Schonhoft JD, Yang J, Gomez G, Ulanet D, Fei K, Koehler M, Yap TA, Højgaard M. Camonsertib monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LOF). ESMO (European Society of Medical Oncology) Congress 2024, September, Barcelona, Spain. (*Oral Presentation*)

90. Sikov M, Lagos G, Holder S, **Carneiro BA**, Mega A, Khaleel S, Golijanin D, Cheng L, de Souza A. Clinical outcomes in metastatic bladder cancer associated with mutations in Tri thorax-group protein genes. ASCO GU 2025 Abstract 835
91. Koffer P, Raker C, DiPetrillo TA, **Carneiro BA**, Mega AE, Sandler HM, Rodrigues GB, Shah AB, Efstathiou JA, Chafe S, Balogh AG, Williams SG, Kuban DA, Gore E, Wong JK, Duclos M, Nguyen PL, Feng FY. Evaluation of post radiotherapy PSA as a prognostic and predictive biomarker in high risk prostate cancer: A secondary analysis of RTOG 0521. ASCO GU 2025 Abstract 384
92. Mantia C, Kim CG, Ahnert J, Alhalabi O, Wei AZ, Stein MN, Johnson ML, Garmez B, Tewari A, Devarakonda S, Tripathi A, **Carneiro BA**, Park I, Boni V, Liu E, Sachdev J, O'Quigley M, White M, Beaupre DM, Kim H. Phase 1 dose escalation (DEs) & expansion (DEX) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel). ASCO GU Abstract TPS892
93. Lin C, Purcell C, Zhang S, Tajiknia V, El-Deiry WS, **Carneiro BA**. Small molecule CB001 downregulates cFLIP, potentiates the effects of androgen receptor inhibitors in prostate cancer models, and enhances NK cell activity. Cancer Res 2025;85(8\_Suppl\_1):Abstract nr 5650.
94. Ghandali M, Zhang L, **Carneiro BA**, El-Deiry WS. Elraglusib (9-ING-41), a glycogen synthase kinase-3 $\beta$  inhibitor in combination with imipridones for treatment of solid cancer. AACR 2025; Cancer Res 2025;85(8\_Suppl\_1):Abstract nr 1693.
95. Purcell C, Zhang L, Ghandali M, Pinho-Schwerrman M, Gyuliane P, Baker BK, Zhou L, Ryspayeva D, **Carneiro BA**, El-Deiry WS. Effect of MTAP expression on PRMT5 inhibitor sensitivity in bladder urothelial carcinoma models. AACR 2025; Cancer Res 2025;85(8\_Suppl\_1):Abstract nr 4239.
96. Ghandali M, Purcell C, Zhang L, Zhou L, Ryspayeva D, Pinho-Schwerrmann M, Baker BK, Gyuliane P, **Carneiro BA**, El-Deiry WS. PRMT5 inhibitor displays synergy with PARP inhibitor in bladder urothelial carcinoma models. AACR 2025; Cancer Res 2025;85(8\_Suppl\_1):Abstract nr 1692.
97. Lin C, Hadfield MJ, Purcell C, Zhang S, Tajiknia V, El-Deiry WS, **Carneiro BA**. Targeting cFLIP to overcome resistance of BRAF V600E melanoma cells with the small molecule CB001 AACR 2025; Cancer Res 2025;85(8\_Suppl\_1):Abstract nr 1592.
98. Pinho-Schwerrmann M, Lin C, Lu S, Zhang S, Srinivasan P, MacDonald W, Purcell C, Hadfield MJ, Lagos G, Tajiknia V, Stubbs N, Meza K, Golijanin D, Hyams E, Mega A, El-Deiry WS, **Carneiro BA**. PARP inhibitor-induced senescent fibroblasts enhance prostate cancer cell proliferation and suppress NK cell-mediated cytotoxicity. AACR 2025; Cancer Res 2025;85(8\_Suppl\_1):Abstract nr 301.
99. Adams M, Trivedi C, Gupta S, Chu J, Petruzzelli C, Malani K, Steuer R, Park W, Madireddy S, Jain S, **Carneiro B**, Hadfield MJ. Incidence and management of steroid-refractory immune checkpoint inhibitor pneumonitis: a single-center retrospective analysis. AACR 2025; Cancer Res 2025;85(8\_Suppl\_1):Abstract nr 5818.
100. Schram AM, Lee EK, Højgaard M, Simpkins F, LoRusso P, Duska LR, Garrido-Laguna I, Weiss MC, Mandilaras V, **Carneiro BA**, Mathews CA, Tymon-Rosario JR, Aguado-Fraile E, Sethuraman S, Soria-Bretones I, Sun X, Basciano PA, Koehler M, Hawkey N, Bacqué ES, Lheureux S, Yap TA. Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656). AACR 2025; Cancer Res 2025;85(8\_Suppl\_2):Abstract nr CT262.

101. Siddiqui BA, Zhang J, **Carneiro BA**, Zarrabi KK, Stein MN, Wise DR, Gelmann EP, Tsao CK, Falchook G, Kim JW, Gao X, Twardowski PW, Rana D, Fang F, Govindraj S, Sims JS, Skokos D, Seebach FA, Lowy I, Thanigaimani P, Ingham M, Sandigursky S, Miller E. Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA×CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). AACR 2025; Cancer Res 2025;85(8\_Suppl\_2):Abstract nr CT064.
102. Weiskittel T, Koukol A, Kellinger C, Ugolkov A, Seifarth C, Li H, Mahalingam D, Zhang L, **Carneiro BA**, El-Deiry WS, Mazar AP. Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 3B) of the GSK-3 inhibitor elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC): Application toward patient enrichment. ASCO 2025 Abstract 4185
103. Mahalingam D, Shroff RT, **Carneiro BA**, Ji Y, Coveler AL, Cervantes A, Sahai V, Ploquin A, Hirt S, LoConte NK, Percent IJ, Lopez CD, Pernot S, Kavan P, Mulcahy MF, Carr RM, Giles FJ, Mazar AP, Fine G, Bekaii-Saab TS. Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). ASCO 2025 Abstract 4006 (Oral Presentation).

## **INVITED PRESENTATIONS**

### **Local:**

1. Best of ASCO 2020, Developmental Therapeutics Module, September 12th, 2020, Providence Downtown Marriott, Providence, RI.
2. Best of ASCO 2020, Developmental Therapeutics and Genitourinary Modules, October 2<sup>nd</sup>, 2021, Providence Downtown Marriott, Providence, RI
3. Urology Grand Rounds, Advanced Prostate Cancer, Department of Urology, Brown Urology, Providence, RI, November 17<sup>th</sup>, 2021
4. Best of ASCO 2023, Developmental Therapeutics and Genitourinary Modules, October 2<sup>nd</sup>, 2021, Providence Downtown Marriott, Providence, R
5. The Impact and Evolution of Oncology Clinical Trials Program at Lifespan. Living Heritage Society, September 11<sup>th</sup>, 2024, Cranston, RI

### **National**

1. Future research in genitourinary malignancies at the Robert H Lurie Comprehensive Cancer Center. Hematology/Oncology Grand Rounds, Division of Hematology/Oncology, Feinberg School of Medicine Northwestern University, January 2015.
2. Personalized medicine and recent developments in phase I research. US Too Prostate Cancer Education Support, Lombard, IL, May 2015.
3. Treatment of advanced prostate cancer, Urology Resident Teaching Conference, Department of Urology, Feinberg School of Medicine Northwestern University, July 2015.

4. Cancer treatment using genome sequencing. Healthnetwork Foundation, Pellston, MI, August 2015.
5. What's old is new again: chemotherapy for the M1 prostate cancer patient. Chicago Urological Society Prostate Cancer Meeting, October 2015.
6. Advances in Lung Cancer Clinical Trials, Lung Force Expo, American Lung Association, Warwick, November 2017
7. 1<sup>st</sup> A. Zamin Rizavi, MD Memorial Lecture, Department of Medicine Grand Rounds, NorthShore University HealthSystem, Evanston, IL, January, 2019
8. GSK3-beta inhibition: bridging a pleiotropic therapeutic target with immune modulation, Department of Melanoma Interdisciplinary Collaboration Meeting, MD Anderson Cancer Center, May 28, 2021
9. Immune modulatory functions of GSK-3b and clinical development of the selective inhibitor 9-ING-41. Helen Diller Family Comprehensive Cancer Center, Early Phase Experimental Therapeutics Program Meeting, University of California San Francisco, August 12<sup>th</sup> 2021.

### **International**

1. Advances in Treatment of Metastatic Breast Cancer. VII Regional Symposium of Breast Surgery, Baturité, CE, September 2010
2. Hormonal Treatment of Advanced Breast Cancer. VII Regional Symposium of Breast Surgery, Baturité, September 2010
3. Molecular Biology Principles for Clinicians. Master's Degree Program, Department of Pathology, School of Medicine, Federal University of Ceará, Fortaleza, CE, November 2010
4. Genetic Counseling for High Risk Breast Cancer Patients. II Breast Cancer Weekend, Cumbuco, CE, March 2011
5. Duration of Combined Hormonal Therapy for Prostate Cancer. IV International Symposium of Urologic Laparoscopic Surgery. Fortaleza, April 2011.
6. Advances in the Treatment of Neuroendocrine Tumors. III General Hospital of Fortaleza Endocrinology Symposium, Fortaleza, August 2011
7. Management of Chemotherapy-Induced Adverse Events in the Elderly. Jornada Cearense de Geriatria e Gerontologia, Fortaleza, October 2011
8. Environmental Cancer Risks. Division of Public Health, School of Medicine, Federal University of Ceará, Fortaleza, November 2011
9. Principles of Chemotherapy. School of Medicine, Faculdade Christus, Fortaleza, CE, May 2012.
10. Hereditary Cancer Syndromes. School of Medicine, Faculdade Christus, Fortaleza, CE, May 2012
11. Treatment and Surveillance of Gastrointestinal Stromal Tumors. XI Meeting of Brazilian Society of Digestive System, Fortaleza, November 2012
12. Treatment Strategies for Advanced Colorectal and Gastric Cancer. III Annual Meeting of Pernambuco Institute of Integrative Medicine (IMIP), Recife, PE, Brazil, October 2012

13. Advances in the Treatment of Metastatic Colorectal Cancer, Recife Gastrointestinal Cancer Symposium, Recife, April 2013
14. Phase I study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3 $\beta$ ) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. Oral presentation at ASCO Annual Meeting, 2020.
15. Best of ASCO Brazilian Edition, Genitourinary Module, June 14<sup>th</sup>, 2021
16. Novel immunotherapy agents in development, National Academy of Medicine (Academia Nacional de Medicina), Cancer Immunotherapy Symposium, Rio de Janeiro, Brazil, June 17<sup>th</sup>, 2021.
17. Homologous Recombination Genes: identification and relevance, 1<sup>st</sup> Precision Medicine Symposium, Sao Paulo, Brazil, September 24<sup>th</sup>, 2021
18. Cochair, Clinical Trials Minisymposium Biomarker Advances in Clinical Trials. The American Association for Cancer Research (AACR) Annual Meeting 2022, New Orleans, Louisiana, April 8-13, 2022
19. Session Chair, Poster Discussion Session, Developmental Therapeutics—Immunotherapy Session, The American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, June 2-7, 2022
20. Camonsertib monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LOF). Oral Presentation at ESMO (European Society of Medical Oncology) Congress 2024, September 13-17, Barcelona, Spain.

## **WORKSHOPS**

- |             |  |
|-------------|--|
| <b>2008</b> | AACR/ASCO Workshop: Methods of Clinical Cancer Research, Vail, Colorado  |
| <b>2009</b> | Cancer Education Consortium, Merrill J. Egorin Workshop in Cancer Therapeutics and Drug Development, Leesburgh, VA |
| <b>2009</b> | Cancer Education Consortium, Molecular and Translational Oncology Workshop, Greensboro, GA.                        |

## **RESEARCH PROJECTS**

### **COMPLETED**

#### ***Funded***

- |                    |  |
|--------------------|--|
| <b>2001 – 2003</b> | Alanyl-Glutamine as oral rehydration & nutrition therapy [Small Business Innovation Research (SBIR) Award] Goal: To investigate the role of stable glutamine derivatives in intestinal epithelial damage repair induced bacterial toxins and chemotherapy. Role: Principal Investigator (SBIR/NIH GRANT R43 DK 58419-01A1) |
| <b>2015 – 2017</b> | Multicenter phase II study of nivolumab (anti-PD-1 antibody) for treatment of metastatic adrenocortical carcinoma. Investigator-initiated trial. Sponsor: Bristol-Myers Squibb. Goal: Investigate the anti-tumor activity of immune checkpoint nivolumab in adrenocortical carcinoma. Role: Principal investigator         |

**2014 – 2017**

Projects in collaboration with Dr. Sarki Abdulkadir's laboratory at Northwestern University. My role as a translational researcher and collaborator in the laboratory was to identify new therapeutic targets in prostate cancer and help guide experiments to inform the development of clinical trials.

1. The Role of DOT1L Inhibitor (EPZ-5676) in preclinical models of castration-resistant prostate cancer (CRPC).
2. Can the PIM inhibitor LGH447 potentiate the anti-tumor effects of the combination of docetaxel and androgen deprivation therapy (ADT) or delay resistance in hormone sensitive prostate cancer preclinical models?
3. Anti-tumor effects of MM-310 (nanoparticle docetaxel) in prostate cancer preclinical models.
4. The effect of antisense against polycomb group protein BMI-1 (B cell-specific Moloney murine leukemia virus integration site 1 protein) in animal models of castration-resistant prostate cancer (CRPC).

**2015 – 2020**

P50 CA180995 (Catalona)

NIH/NCI SPORE in Prostate Cancer Project 3

The four proposed projects refine our ability to detect lethal prostate cancer (Project 1), identify additional biomarkers for disease aggressiveness and response to targeted therapy in personalized medicine (Projects 1-4) and improve therapy for castrate-resistant prostate cancer (Projects 2-4) in translational cancer research.

Role: Collaborator leading the development and implementation of a Phase II study evaluating the soluble decoy Ephrin B4 receptor-human serum albumin fusion protein (sEphB4-HSA) in castration-resistant prostate cancer (NCT04033432). Principal investigator for this trial that emerged from Dr. Sarki Abdulkadir's laboratory preclinical results (PI – Prostate Cancer Project 3). Direct amount: \$150,000

**2018 – present**

**Projects at Brown University in collaboration with Wafik El-Deiry, MD, PhD translational cancer therapeutics laboratory**

The therapeutic synergy between androgen receptor antagonists and small molecule ONC201 in preclinical models of prostate cancer. The results of this ongoing project provided the rationale for an investigator-initiated study in advanced prostate cancer.

Combination of ONC201 with TRAIL agonist TLY012 as a novel therapeutic strategy in solid tumors. Preclinical results of this funded project supported the development of the investigator-initiated trial BrUOG 383: A Phase Ib/II Single Arm Open Label Investigator-Initiated Therapeutic Clinical Study of ONC201 plus TLY012 (SQ TRAIL) in advanced solid tumors.

Novel immune-modulatory functions of Glycogen Synthase Kinase 3 (GSK-3) in preclinical in vitro and animal cancer models. This project was the topic of Kelsey Huntington's PhD thesis at El-Deiry's lab.

## ONGOING

- 2024 Investigating cellular senescence as a mechanism of treatment resistance in prostate cancer. Legorreta Cancer Center Translational Pilot Project.  
Co-PI (\$20,000)  
The goal of this project is to characterize senescence markers in prostate cancer tumor specimens and investigate the role of therapy-induced senescence in the development of castration resistance in prostate cancer.
- 2024 Characterization of MTAP-deleted and wild-type urothelial carcinomas and development of organoids from fresh specimens from MTAP-deleted urothelial carcinoma for drug screens. (\$861,300)  
Co-PI. Support from Astra-Zeneca.

## CLINICAL TRIALS

2015—2017

*Local principal investigator for the following national and international clinical trials at Northwestern University.*

1. Randomized Phase III Trial Comparing-Dose Chemotherapy Using paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by high-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors (Alliance A031102).  
Sponsor: National Cancer Institute
2. Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (SWOG 1216). Sponsor: National Cancer Institute
3. SWOG 1500: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (SWOG 1500). Sponsor: National Cancer Institute
4. Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors. Sponsor: MedImmune, LLC.
5. Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors. Sponsor: MedImmune, LLC.



6. An open label, non-randomized, Phase I dose escalation study to characterize safety, tolerability, pharmacokinetics and maximum tolerated dose of BAY 1163877 in subjects with refractory, locally advanced or metastatic solid tumors 2016. Sponsor: Bayer
7. Phase I study evaluating the safety, pharmacology and preliminary activity of the co-administration of MM-151 and MM-121 in heregulin positive cancer patients. Sponsor: Merrimack Pharmaceuticals
8. Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC). Sponsor: Merck
9. Phase III randomized, controlled clinical trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced or metastatic urothelial carcinoma. Sponsor: Merck
10. Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects with Advanced Cancers. Sponsor: Abbvie
11. Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer. Sponsor: Prostate Cancer Clinical Trials Consortium.
12. Randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer. Sponsor: University of Michigan.

## **2017— present**

### ***Principal investigator for the following national and international studies at Brown University***

1. A Phase 1b/2 open-label study to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with advanced malignancies. Sponsor: Pfizer. 2018-2022
2. An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies (M15-438). Sponsor: Abbvie. 2018-2022.
3. A Phase 1 Study of Durvalumab and IPH2201 (monalizumab) in Adult Subjects with Select Advanced Solid Tumors (D419NC00001). Sponsor: MedImmune. 2018-2022
4. A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth

- Factor Receptor (EGFR) or its Ligands (M16-438). Sponsor: Abbvie. 2018-2021
5. A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination with Durvalumab in Selected Advanced Solid Tumors. Sponsor: MedImmune. 2018-2021
  6. An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). Sponsor: Astellas. 2019-2021.
  7. A Phase 1/2 Study of the Oral CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer. Sponsor: UCSF, Prostate Cancer Clinical Trials Consortium. 2018-2021.
  8. A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors. Sponsor: Abbvie. 2019-2024.
  9. Phase II study of Optimized Management of NIVolumab based on REsponse in patients with advanced renal cell carcinoma. Sponsor: Dana Farber Cancer Institute. 2018-2021
  10. Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3 $\beta$ ) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors. Sponsor: Actuate Therapeutics. 2018-present
  11. An Open-Label, Multi-Center, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Copanlisib in Combination with Nivolumab in Patients with Advanced Solid Tumors. Sponsor: Bayer. 2019-2023
  12. A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Solid Tumors. Sponsor: MedImmune. 2019-2023.
  13. BrUOG 360: A Phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer. **Investigator-initiated trial**. Sponsors: Bayer and Clovis. 2020-present
  14. A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab  $\pm$  Oleclumab in Advanced Solid Tumors (D6770C00001). Sponsor: AstraZeneca. 2020-2022.
  15. An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination with Durvalumab in Subjects with Select Advanced Solid Tumors (D6450C00001). Sponsor: AstraZeneca. 2020-2023.
  16. A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a monotherapy and in combination with Pembrolizumab in Patients

- With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications. Sponsor: Dragonfly Therapeutics. 2020-present
17. Phase 1/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib in Advanced Solid Tumors with ATR inhibitor Sensitizing Mutations. Sponsor: Repare Therapeutics. 2021-2025.
  18. A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors. Sponsor: Abbvie. 6/2021-present.
  19. A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors. Sponsor: Astra Zeneca. 4/2021-present.
  20. A Phase II study of carboplatin, cabazitaxel and abiraterone in high volume metastatic castration sensitive prostate cancer. Sponsor: Prostate Cancer Clinical Trials Consortium (PCCTC). 2021-present
  21. Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study: PKMYT1 Inhibition for the Treatment of Cancers). Sponsor: Repare Therapeutics. 2022-present
  22. A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients with Advanced Solid Tumors. Sponsor: Agenus. 2022-2024
  23. A Phase 1 Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer (iNKT) Non-Transduced Cells (agenT-797) as a Single Agent and in Combination with Approved Immune Checkpoint Inhibitors in Patients with Relapsed/ Refractory Solid Tumors. Sponsor: Agenus. 2022-2024.
  24. Phase 1 A Phase 1 study of REGN5678 (anti-PSMAXCD28) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer. Sponsor: Regeneron. 2022-present.
  25. A Phase I first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors. Sponsor: Abbvie. 2022-2024.
  26. A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors known to Express NY-ESO-1. Sponsor: Astellas. 2022-2023.
  27. A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors. Sponsor: Agenus. 2022-2024
  28. A Phase I/IIa First-in-human, Open-label, Modular Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8853. Sponsor: AstraZeneca. 2022-2024.
  29. An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A

- Inhibitor) In Adult Participants with Advanced Solid Tumors. Sponsor: Ideaya Biosciences. 2023-2025.
30. A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of PYX-201 in Participants with Advanced Solid Tumors. Sponsor: Pyxis Oncology. 2023-present.
  31. A phase I, multicenter, open-label study of TY-2136b, administered orally in patients with advanced or metastatic solid tumors harboring ALK, ROS1 or NTRK1-3 alterations. Sponsor: TYK Medicines. 2023.
  32. Phase 1/2 open-label, multicenter, first-in-human study of DS-3939a in subjects with advanced solid tumors. Sponsor: Daiichi-Sankyo. 2023-present.
  33. A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors. Sponsor: Roche. 2023-present.
  34. A Phase 1/1b, First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients with Advanced Solid Tumors. Sponsor: Dragonfly. 2023-present
  35. A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors. Sponsor: Numab Therapeutics. 2024-2025.
  36. A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors. Sponsor: Incyte. 2023-present.
  37. An Open-label, Phase I Study to Investigate the Biological Effects of AZD5305 Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer. Sponsor: AstraZeneca. 2024-present
  38. A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer. Sponsor: AstraZeneca. 2024-present
  39. A phase I, open-label, multicenter study of JANX007 in subjects with metastatic castration-resistant prostate cancer. Sponsor: Janux Therapeutics. 2024-present
  40. A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects with Advanced Solid Tumors. Sponsor: Pyxis Oncology. 2024-2025.
  41. Metastatic castration-resistant prostate cancer: first-in-human study of ABBV-969 in metastatic castration-resistant prostate cancer. Sponsor: Abbvie. 2023-present
  42. A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours that are MTAP Deficient. Sponsor: AstraZeneca. 2024-present

43. A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 as a Single Agent in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair. Sponsor: Nimbus Therapeutics. 2025-present.
44. A first-in-human, Phase 1/2, dose-escalation, and a dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, as monotherapy and in combination in participants with advanced solid tumors. Sponsor: Eikon Therapeutics. 2024-present
45. A Phase I, first-in-human, open-label, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of BNT317 in patients with advanced solid tumors. Sponsor: BioNTech. 2025-present.
46. Phase 1 study of ACR-2316 in subjects with advanced solid Tumors. Sponsor: Acrivon Therapeutics. 2025-present
47. A phase I study to evaluate safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of RO7567132 as single agent and in combination with atezolizumab in participants with advanced and/or metastatic solid tumors. Sponsor: Roche. 2025-present.

***Co-investigator for the following clinical trials at Brown University (selected trials)***

1. BrUOG 387: Phase Ib investigator-initiated trial of heat shock protein 90 inhibitor TAS-116 (pimipitspib) combined with cyclin-dependent kinase 4/6 inhibitor palbociclib in advanced breast cancer progressing on palbociclib and treatment-refractory solid tumors with retinoblastoma (Rb) Deficiency. Role: Co-Investigator. 2024.
2. BrUOG 354: A phase II randomized trial of nivolumab +/- ipilimumab for ovarian and extra-renal clear cell carcinomas. Role: Co-Investigator. 2023.
3. BrUOG 379: A Phase Ib/II Single Arm Study of ONC201 plus Nivolumab in Microsatellite Stable (MSS) metastatic colorectal cancer (mCRC) patients. Role: Co-Investigator. 2021.
4. BrUOG 428: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant (TASUC-Neo). A Pilot Study of Degarelix in Combination with Neoadjuvant Gemcitabine and Cisplatin in Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. Role: Co-Investigator. 2023.
5. A Phase 1/1b Study of ASP2074 in Participants with Metastatic or Locally Advanced Solid Tumors. Role: Co-Investigator. 2024.
6. A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine with or without Botensilimab (AGEN1811) in Patients with Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX). Role: Co-Investigator. 2023.

7. A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a monotherapy and in combination with nivolumab in Patients with Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications. Role: Co-Investigator. 2022.
8. A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103A Combination Therapy in Subjects with Advanced Solid Tumors (DS-1103A Combination Therapy First-Inhuman Study). Role: Co-Investigator.
9. A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications. Role: Co-Investigator. 2020.
10. A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications. Role: Co-Investigator. 2024.
11. A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination with Anti-cancer Agents in Participants with Solid Tumors. Role: Co-Investigator. 2024.
12. First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF driven; Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors. Role: Co-Investigator. 2023.
13. A Phase 1/2, Open Label, First-In-Human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of SAR445877 Administered as Monotherapy in Adults with Advanced Solid Tumors. Role: Co-Investigator. 2023.
14. A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors. Role: Co-Investigator. 2023.
15. A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies. Role: Co-Investigator. 2022.
16. A Phase 1/2 Open-Label, First-In-Human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of SAR444200-Based Regimen in Participants with Advanced Solid Tumors. Role: Co-Investigator. 2023.

17. A Phase I, Multicenter, Open-label, First-in Human, Dose escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors. Role: Co-Investigator. 2023.
18. A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) for the Treatment of Advanced, Refractory Microsatellite Stable Colorectal Cancer without Liver Metastases. Role: Co-Investigator. 2023.
19. An Open-Label, Single-Arm, Multi-Center Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1904 in Subjects with Advanced Solid Tumors Expressing Claudin 18.2. Role: Co-Investigator. 2022.
20. A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors. Role: Co-Investigator. 2020.
21. Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. Role: Co-Investigator. 2023.
22. NRG-GU009: Parallel Phase III Randomized Trials for High-Risk Prostate Cancer Evaluating De Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT). Role: Co-Investigator. 2022.
23. A031701: A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations. Role: Co-Investigator. 2023.
24. A031701: A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations. Role: Co-Investigator. 2023.

### **UNIVERSITY TEACHING ROLES**

<b>2009</b>	Oncology Course, University of Pittsburgh School of Medicine, October 2009.
<b>2010</b>	Advanced Physical Examination Course, University of Pittsburgh School of Medicine, March 2010.
<b>2015</b>	Problem Based Learning Course Facilitator, Northwestern University Feinberg School of Medicine
<b>2015 – 2017</b>	Science in Medicine Hematology/Oncology Lecture Series, Second Year Medical Students, Northwestern University Feinberg School of Medicine
<b>2017 – present</b>	Hematology/Oncology Fellows, Division of Hematology/Oncology, Brown University. Supervision of outpatient clinic, fellow weekly tumor board and inpatient consultations.

**Faculty mentoring:**

Andre De Souza, MD

Assistant Professor, Division of Hematology/Oncology

Characterization of advanced urothelial carcinoma with 9q21 deletion

Bradley D. DeNardo, MD

Assistant Professor, Pediatric Hematology/Oncology

BrUOG 398: Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3 $\beta$ ) Inhibitor, Combined with Chemotherapy, in Patients with Advanced Sarcomas. *Investigator-initiated study*

Sheldon Holder, MD, PhD

Assistant Professor, Department of Pathology and Laboratory Medicine & Division of Hematology/Oncology, Brown University

Integration community-based participatory research (CBPR) into genitourinary cancer clinical trials program.

Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program (PI: Sheldon Holder).

10/2021-11/2023; \$120,000/yr

Role: co-mentor

**Hematology/Oncology Fellows:**

Ilyas Sahin, MD (2017-2020)

Development of clinical studies in castration-resistant prostate cancer.

BrUOG 360: Phase Ib/II study of copanlisib and olaparib in patients with metastatic castration-resistant prostate cancer carrying mutations in DNA repair genes. The concept has been approved, and the clinical trial is ongoing.

Eric Marks, MD (2017-2020)

Impact of mutations in DNA repair genes in the outcomes of metastatic colorectal cancer patients treated with FOLFOX and FOLFIRI.

Results published on the American Journal of Clinical Oncology.

Kathryn DeCarli, MD (2021-2023)

Impact of a physician-led supportive care intervention among oncology patients on phase I clinical trials

Matthew Hadfield, MD (2021-2024)

Strategies to overcome DNA repair inhibitor-induced senescence-mediated resistance in the tumor microenvironment

**Internal Medicine Residents:**

Robert Matera, MD (2018-2020)



Prospective evaluation of mechanisms of resistance to PARP inhibitors in patients with solid malignancies.

Angela Koh, MD (2025-present)

Predictive biomarkers of response and resistance to PSMA-targeted therapies and other modalities for advanced prostate cancer

#### **Brown medical students:**

Brittany Borden (Class 2022)

Landscape of molecular alterations in the Glycogen synthase kinase-3 gene in solid organ malignancies. Project selected for oral presentation at the Alpert Medical School Research Symposium, November 2019 and published in the journal Molecular Cancer Therapeutics (PMID 33087512).

Luke Soliman (Class 2023)

Differential gene expression profiling between primary tumors and metastatic sites in advanced prostate cancer.

Project received the award recognizing the most outstanding presentation in Basic Sciences at the 13th Annual Warren Alpert Medical School Academic Symposium, November 2020.

Praveen Srinivasan (Class 2023)

Characterizing the molecular alterations in the extrinsic apoptosis pathway in metastatic bladder cancer and their relationship to tumor response to immunotherapy.

Claire Lin (Class 2027)

The role of cFLIP in the treatment of castration-resistant prostate cancer models. Posters accepted at the 2025 AACR Annual Meeting.

#### **Brown undergraduate students:**

Amol Rathore (Class 2027)

Characterization of cellular senescence in prostate cancer.

#### **Post-doctoral students and visiting scholars:**

Fabio Tavora, MD, PhD (6/2019-1/2020)

Role of Glycogen Synthase Kinase-3 inhibitor 9-ING-41 in preclinical models of prostate cancer and clinical specimens from patients with advanced prostate cancer.

Maximilian Pinho Schwermann, MD (4/2022-5/2024)

Effect of androgen signaling on the regulation of T and NK cells.

#### **Teaching Awards:**

**2016**

Feinberg School of Medicine Excellence in Teaching Award, Division of Hematology/Oncology, Department of Medicine, Northwestern University

#### **Laboratory and other research supervisory and training responsibilities:**

<b>2015 – 2017</b>	Sahithi Pamarthi, PhD and Vinay Sagar, PhD. Position: Post-doctoral research fellow at the Developmental Therapeutics Program, Northwestern University. Co-mentored with Sarki Abdulkadir, MD, PhD. Preclinical studies investigating novel therapeutic targets in prostate cancer.
<b>2015 – 2017</b>	Ami Shah, MD. Position: Hematology/Oncology fellow at Northwestern University. Protocol development of a phase II study evaluating the decoy Ephrin B4 receptor-human serum albumin fusion protein (sEphB4-HSA) for the treatment of patients with castration-resistant prostate cancer. Dr Shah was selected to participate at the ASCO/AACR Methods in Clinical Research Workshop (Veil, CO 2017) with this proposal. Current position: Assistant Professor at the Division of Hematology/Oncology, Northwestern University.
<b>2016</b>	Zachary Reinstein, undergraduate student, Brigham Young University <i>Recipient</i> , 2017-2018 American Association for Cancer Research (AACR)-Thomas J. Bardos Science Education Scholar Award. Summer project in collaboration with Sarki Abdulkadir, MD, PhD. Project evaluating combinations of PARP inhibitors with androgen pathway blockers for treatment of prostate cancer. Zachary was accepted to the Medical Scientist Training Program at the Feinberg School of Medicine, Northwestern University (2017).

### **HOSPITAL TEACHING ROLES**

<b>2010 - 2014</b>	Medical Oncology Inpatient Consult Service, Hospital Geral de Fortaleza, Internal Medicine and General Surgery Residency Programs.
<b>2010 - 2014</b>	Preceptorship of Medical Students, Internal Medicine Interns and Residents, Hospital Geral de Fortaleza, Medical Oncology Outpatient Clinic.
<b>2010 - 2014</b>	Invited Lecturer, Oncology Course, School of Medicine, Faculdade Christus, Fortaleza, CE
<b>2015 - 2017</b>	Inpatient Oncology Service, Northwestern Memorial Hospital (2 months/yr).
<b>2017- present</b>	Hematology/Oncology Inpatient Service, The Miriam Hospital and Rhode Island Hospital, Division of Hematology/Oncology